üè• Healthcare MCP Server Test Suite
==================================

[1;33mTesting: Health Check[0m
[0;32m‚úì PASS[0m (HTTP 200)
{
  "status": "healthy",
  "service": "healthcare-mcp",
  "timestamp": "2025-08-04T16:15:24.875Z"
}

[1;33mTesting: Tools List[0m
[0;32m‚úì PASS[0m (HTTP 200)
{
  "jsonrpc": "2.0",
  "result": {
    "tools": [
      {
        "name": "find_patient",
        "description": "Search for a patient by demographics",
        "inputSchema": {
          "type": "object",
          "properties": {
            "lastName": {
              "type": "string"
            },
            "firstName": {
              "type": "string"
            },
            "birthDate": {
              "type": "string",
              "description": "YYYY-MM-DD format"
            },
            "gender": {
              "type": "string",
              "enum": [
                "male",
                "female",
                "other",
                "unknown"
              ]
            }
          },
          "required": [
            "lastName"
          ]
        }
      },
      {
        "name": "get_patient_observations",
        "description": "Get observations (vitals, labs) for a patient",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "code": {
              "type": "string",
              "description": "LOINC or SNOMED code"
            },
            "dateFrom": {
              "type": "string",
              "description": "YYYY-MM-DD"
            },
            "dateTo": {
              "type": "string",
              "description": "YYYY-MM-DD"
            },
            "status": {
              "type": "string",
              "enum": [
                "registered",
                "preliminary",
                "final",
                "amended",
                "corrected",
                "cancelled"
              ]
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_patient_conditions",
        "description": "Get medical conditions/diagnoses for a patient",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "status": {
              "type": "string",
              "enum": [
                "active",
                "inactive",
                "resolved"
              ]
            },
            "onsetDate": {
              "type": "string",
              "description": "YYYY-MM-DD"
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_patient_medications",
        "description": "Get medication orders for a patient",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "status": {
              "type": "string",
              "enum": [
                "active",
                "completed",
                "stopped",
                "on-hold"
              ]
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_patient_encounters",
        "description": "Get healthcare encounters/visits for a patient",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "status": {
              "type": "string",
              "enum": [
                "planned",
                "arrived",
                "in-progress",
                "finished",
                "cancelled"
              ]
            },
            "dateFrom": {
              "type": "string",
              "description": "YYYY-MM-DD"
            },
            "dateTo": {
              "type": "string",
              "description": "YYYY-MM-DD"
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_patient_allergies",
        "description": "Get allergies and intolerances for a patient",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "status": {
              "type": "string",
              "enum": [
                "active",
                "inactive",
                "resolved"
              ]
            },
            "type": {
              "type": "string",
              "enum": [
                "allergy",
                "intolerance"
              ]
            },
            "category": {
              "type": "string",
              "enum": [
                "food",
                "medication",
                "environment",
                "biologic"
              ]
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_patient_procedures",
        "description": "Get procedures performed on a patient",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "status": {
              "type": "string",
              "enum": [
                "preparation",
                "in-progress",
                "completed",
                "entered-in-error"
              ]
            },
            "dateFrom": {
              "type": "string",
              "description": "YYYY-MM-DD"
            },
            "dateTo": {
              "type": "string",
              "description": "YYYY-MM-DD"
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_patient_careplans",
        "description": "Get care plans for a patient",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "status": {
              "type": "string",
              "enum": [
                "draft",
                "active",
                "suspended",
                "completed",
                "cancelled"
              ]
            },
            "category": {
              "type": "string"
            },
            "dateFrom": {
              "type": "string",
              "description": "YYYY-MM-DD"
            },
            "dateTo": {
              "type": "string",
              "description": "YYYY-MM-DD"
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_vital_signs",
        "description": "Get patient's vital signs history",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "timeframe": {
              "type": "string",
              "description": "e.g., 3m, 6m, 1y, all"
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_lab_results",
        "description": "Get patient's lab results",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "category": {
              "type": "string",
              "description": "e.g., CBC, METABOLIC, LIPIDS, ALL"
            },
            "timeframe": {
              "type": "string"
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_medications_history",
        "description": "Get patient's medication history including changes",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "includeDiscontinued": {
              "type": "boolean"
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "get_appointments",
        "description": "Get patient's Appointments",
        "inputSchema": {
          "type": "object",
          "properties": {
            "patientId": {
              "type": "string"
            },
            "dateFrom": {
              "type": "string",
              "description": "YYYY-MM-DD"
            },
            "dateTo": {
              "type": "string",
              "description": "YYYY-MM-DD"
            }
          },
          "required": [
            "patientId"
          ]
        }
      },
      {
        "name": "search-pubmed",
        "description": "Search PubMed for medical literature",
        "inputSchema": {
          "type": "object",
          "properties": {
            "query": {
              "type": "string"
            },
            "maxResults": {
              "type": "number"
            }
          },
          "required": [
            "query"
          ]
        }
      },
      {
        "name": "search-trials",
        "description": "Search ClinicalTrials.gov for relevant studies",
        "inputSchema": {
          "type": "object",
          "properties": {
            "condition": {
              "type": "string"
            },
            "location": {
              "type": "string"
            }
          },
          "required": [
            "condition"
          ]
        }
      },
      {
        "name": "get-drug-info",
        "description": "Get Drug details by a generic name",
        "inputSchema": {
          "type": "object",
          "properties": {
            "genericName": {
              "type": "string"
            }
          },
          "required": [
            "genericName"
          ]
        }
      }
    ]
  },
  "id": 1
}

[1;33mTesting: PubMed Search[0m
[0;32m‚úì PASS[0m (HTTP 200)
{
  "jsonrpc": "2.0",
  "result": {
    "content": [
      {
        "type": "text",
        "text": "Error executing search-pubmed: Cannot read properties of undefined (reading 'idlist')"
      }
    ],
    "isError": true
  },
  "id": 1
}

[1;33mTesting: Clinical Trials Search[0m
[0;32m‚úì PASS[0m (HTTP 200)
{
  "jsonrpc": "2.0",
  "result": {
    "content": [
      {
        "type": "text",
        "text": "[\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT00001612\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"970120\"\n        },\n        \"secondaryIdInfos\": [\n          {\n            \"id\": \"97-EI-0120\"\n          }\n        ],\n        \"organization\": {\n          \"fullName\": \"National Institutes of Health Clinical Center (CC)\",\n          \"class\": \"NIH\"\n        },\n        \"briefTitle\": \"Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)\",\n        \"officialTitle\": \"Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"1999-05\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"1997-05\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2000-08\"\n        },\n        \"studyFirstSubmitDate\": \"1999-11-03\",\n        \"studyFirstSubmitQcDate\": \"2002-12-09\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2002-12-10\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"lastUpdateSubmitDate\": \"2008-03-03\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2008-03-04\",\n          \"type\": \"ESTIMATED\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"leadSponsor\": {\n          \"name\": \"National Eye Institute (NEI)\",\n          \"class\": \"NIH\"\n        }\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"Patients enrolled in the original Early Treatment Diabetic Retinopathy Study at the Clinical Center at Johns Hopkins Wilmer Eye Institute will be invited for a follow-up visit at the National Eye Institute. Visual function will be assessed with manifest refraction and standardized visual acuity measurement. The progression of retinopathy will be evaluated by ocular exam and fundus photography. A brief medical history will be obtained. The goal of this study is to evaluate the long-term results of patients whose diabetic retinopathy was treated with different strategies of scatter and/or focal laser photocoagulation.\",\n        \"detailedDescription\": \"To evaluate the long-term clinical course and prognosis of diabetic retinopathy treated with different strategies of scatter and/or focal laser photocoagulation in patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS).\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Diabetic Retinopathy\"\n        ],\n        \"keywords\": [\n          \"Diabetic Retinopathy\",\n          \"Long-Term Visual Outcome\",\n          \"Photocoagulation\",\n          \"J. H. Wilmer Eye Institute\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"OBSERVATIONAL\",\n        \"enrollmentInfo\": {\n          \"count\": 170\n        }\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Patient was originally enrolled in the Early Treatment Diabetic Retinopathy Study at the Johns Hopkins Wilmer Eye Institute.\\n\\nPatient not previously enrolled are not eligible.\",\n        \"healthyVolunteers\": false,\n        \"sex\": \"ALL\",\n        \"stdAges\": [\n          \"CHILD\",\n          \"ADULT\",\n          \"OLDER_ADULT\"\n        ]\n      },\n      \"contactsLocationsModule\": {\n        \"locations\": [\n          {\n            \"facility\": \"National Eye Institute (NEI)\",\n            \"city\": \"Bethesda\",\n            \"state\": \"Maryland\",\n            \"zip\": \"20892\",\n            \"country\": \"United States\",\n            \"geoPoint\": {\n              \"lat\": 38.98067,\n              \"lon\": -77.10026\n            }\n          }\n        ]\n      },\n      \"referencesModule\": {\n        \"references\": [\n          {\n            \"pmid\": \"8437309\",\n            \"type\": \"BACKGROUND\",\n            \"citation\": \"Ferris FL 3rd. How effective are treatments for diabetic retinopathy? JAMA. 1993 Mar 10;269(10):1290-1. No abstract available.\"\n          }\n        ]\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D012164\",\n            \"term\": \"Retinal Diseases\"\n          },\n          {\n            \"id\": \"D003930\",\n            \"term\": \"Diabetic Retinopathy\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D005128\",\n            \"term\": \"Eye Diseases\"\n          },\n          {\n            \"id\": \"D003925\",\n            \"term\": \"Diabetic Angiopathies\"\n          },\n          {\n            \"id\": \"D014652\",\n            \"term\": \"Vascular Diseases\"\n          },\n          {\n            \"id\": \"D002318\",\n            \"term\": \"Cardiovascular Diseases\"\n          },\n          {\n            \"id\": \"D048909\",\n            \"term\": \"Diabetes Complications\"\n          },\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M14999\",\n            \"name\": \"Retinal Diseases\",\n            \"asFound\": \"Retinopathy\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7125\",\n            \"name\": \"Diabetic Retinopathy\",\n            \"asFound\": \"Diabetic Retinopathy\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M8271\",\n            \"name\": \"Eye Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7120\",\n            \"name\": \"Diabetic Angiopathies\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M17400\",\n            \"name\": \"Vascular Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M26004\",\n            \"name\": \"Diabetes Complications\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC11\",\n            \"name\": \"Eye Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          },\n          {\n            \"abbrev\": \"BC14\",\n            \"name\": \"Heart and Blood Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT02691312\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"IRB201501086\"\n        },\n        \"organization\": {\n          \"fullName\": \"University of Florida\",\n          \"class\": \"OTHER\"\n        },\n        \"briefTitle\": \"Pediatric Type 1 Diabetes and Retinopathy\",\n        \"officialTitle\": \"Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2019-12\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2016-07\",\n          \"type\": \"ACTUAL\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2018-01-20\",\n          \"type\": \"ACTUAL\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2018-12-27\",\n          \"type\": \"ACTUAL\"\n        },\n        \"studyFirstSubmitDate\": \"2016-02-22\",\n        \"studyFirstSubmitQcDate\": \"2016-02-22\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2016-02-25\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"lastUpdateSubmitDate\": \"2019-12-11\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2019-12-12\",\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"type\": \"SPONSOR\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"University of Florida\",\n          \"class\": \"OTHER\"\n        }\n      },\n      \"oversightModule\": {\n        \"oversightHasDmc\": false,\n        \"isFdaRegulatedDrug\": false,\n        \"isFdaRegulatedDevice\": false\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"Diabetic retinopathy (DR) causes more new cases of blindness among young adults than any other disease. More than 90% of individuals with type 1 diabetes (T1D) will have some form of DR by 20 years after their diagnosis. DR is associated with long-term hyperglycemia and blood glucose variability, which induces vascular endothelial dysfunction and destruction in the retina, eventual retinal ischemia, and in the end, widespread neovascularization of the retina and optic disk. When these fragile vessels bleed, they can cause vitreous hemorrhage and loss of vision. Eventually the friable vessels fibrose and can result in retinal detachment or further retinal ischemia.\\n\\nMajor risk factors for the development of diabetic retinopathy are time since diagnosis, age at diagnosis, and severity of hyperglycemia. Retinopathy most commonly occurs at least three years after diagnosis and most cases are diagnosed more than five years after the onset of T1D. Current guidelines from the American Diabetes Association (ADA) and American Academy of Ophthalmology (AAO) recommend that patients with T1D undergo an initial comprehensive dilated fundoscopic evaluation once the individual has had diabetes for 3-5 years and has either reached puberty or 10 years of age, whichever is earlier. These patients should receive a yearly exam thereafter, or every two years based upon the recommendation of an eye care professional. However, the prevalence of retinopathy in children is unknown and adherence to these guidelines, especially in youth, has proven difficult. Thus, it is important to make these guidelines more evidence based, as retinopathy is often asymptomatic until vision loss occurs. The first step in this process is the determination of the prevalence of retinopathy in a general population of youth with diabetes. This should be followed by determining which children are most at risk, so the guidelines can provide realistic and pertinent guidance to practitioners.\",\n        \"detailedDescription\": \"The study will be a prospective cross-sectional study of pediatric participants who have had T1D for one year or more. Pediatric participants will be recruited at the Florida Diabetes Camps, the Children With Diabetes Friends for Life Orlando Conference, and the University of Florida Pediatric Endocrinology Clinics. The participants will be tested for diabetic retinopathy using a Digital Retinography System (DRS) (http://www.centervue.com/producta556.html?id=637). The DRS is a portable non-mydriatic fundus camera in which the participants places their chins on the chin-rest and the device takes a digital image of their eyes for evaluation by an ophthalmologist remotely. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.\\n\\nAs part of their informed consent, all participants will be asked as part of their informed consent to allow study staff to contact their local ophthalmologist for their eye exam results following a positive or inconclusive portable retinal screening. Participants or their guardians will also be asked to fill out a study questionnaire during the screening visit. When available, the study subjects' medical record will be accessed to identify their BMI, time since T1D diagnosis, previous hemoglobin A1c (HbA1c) levels over the last 12 months (or longer if available), insulin regimen, Tanner staging, serum lipids, urine microalbumin:creatinine, presence or absence of hypertension, and previous diagnoses of diabetic retinopathy, microalbuminuria, hyperlipidemia or hypertension.\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Diabetic Retinopathy\"\n        ],\n        \"keywords\": [\n          \"type 1 diabetes\",\n          \"retinopathy\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"OBSERVATIONAL\",\n        \"patientRegistry\": false,\n        \"designInfo\": {\n          \"observationalModel\": \"CASE_ONLY\",\n          \"timePerspective\": \"CROSS_SECTIONAL\"\n        },\n        \"enrollmentInfo\": {\n          \"count\": 500,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"armsInterventionsModule\": {\n        \"armGroups\": [\n          {\n            \"label\": \"Type 1 diabetes (T1D)\",\n            \"description\": \"Pediatric patients with type 1 diabetes (T1D) will have an eye exam using the Digital Retinography System (DRS) taking non-mydriatic fundus images. If the test is positive or inconclusive, subjects will be notified and referred to an ophthalmologist for a dilated retinal exam. A chart review and questionnaire will be completed to evaluate for risk factors predisposing subjects to diabetic retinopathy.\",\n            \"interventionNames\": [\n              \"Device: Digital Retinography System\"\n            ]\n          }\n        ],\n        \"interventions\": [\n          {\n            \"type\": \"DEVICE\",\n            \"name\": \"Digital Retinography System\",\n            \"description\": \"The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.\",\n            \"armGroupLabels\": [\n              \"Type 1 diabetes (T1D)\"\n            ],\n            \"otherNames\": [\n              \"CenterVue Digital Retinography System\",\n              \"DRS\"\n            ]\n          }\n        ]\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"Number of participants diagnosed with retinopathy\",\n            \"description\": \"Using a CenterVue Digital Retinography System (DRS) the participants with a positive or inconclusive screen will be called with the results and recommended to undergo a dilated eye examination by a skilled ophthalmologist. The results from the ophthalmologist will be compared to the DRS results.\",\n            \"timeFrame\": \"Baseline\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* Diagnosis of type 1 diabetes\\n* Duration of diabetes 1 year or greater\\n\\nExclusion Criteria:\\n\\n* Diabetes less than 1 year duration\\n* Age \\\\< 9 years and \\\\>26 years of age\",\n        \"healthyVolunteers\": false,\n        \"sex\": \"ALL\",\n        \"minimumAge\": \"9 Years\",\n        \"maximumAge\": \"26 Years\",\n        \"stdAges\": [\n          \"CHILD\",\n          \"ADULT\"\n        ],\n        \"studyPopulation\": \"People with type 1 diabetes and a duration of 1 year or greater will be asked to participate. Potential participants will be approached at the Pediatric Endocrinology clinic visits, Florida Diabetes Camp and the Children With Diabetes annual meeting.\",\n        \"samplingMethod\": \"NON_PROBABILITY_SAMPLE\"\n      },\n      \"contactsLocationsModule\": {\n        \"overallOfficials\": [\n          {\n            \"name\": \"Janet H Silverstein, MD\",\n            \"affiliation\": \"University of Florida\",\n            \"role\": \"PRINCIPAL_INVESTIGATOR\"\n          }\n        ],\n        \"locations\": [\n          {\n            \"facility\": \"Florida Diabetes Camps\",\n            \"city\": \"De Leon Springs\",\n            \"state\": \"Florida\",\n            \"zip\": \"32130\",\n            \"country\": \"United States\",\n            \"geoPoint\": {\n              \"lat\": 29.11989,\n              \"lon\": -81.35286\n            }\n          },\n          {\n            \"facility\": \"Pediatrics Endocrinology/Diabetes at UF Health Medical Plaza and Children's Medical Services Building\",\n            \"city\": \"Gainesville\",\n            \"state\": \"Florida\",\n            \"zip\": \"32611\",\n            \"country\": \"United States\",\n            \"geoPoint\": {\n              \"lat\": 29.65163,\n              \"lon\": -82.32483\n            }\n          },\n          {\n            \"facility\": \"Children With Diabetes Friends For Life Conference\",\n            \"city\": \"Orlando\",\n            \"state\": \"Florida\",\n            \"zip\": \"32821\",\n            \"country\": \"United States\",\n            \"geoPoint\": {\n              \"lat\": 28.53834,\n              \"lon\": -81.37924\n            }\n          }\n        ]\n      },\n      \"referencesModule\": {\n        \"availIpds\": [\n          {\n            \"type\": \"FDA 501(k)\",\n            \"url\": \"https://www.accessdata.fda.gov/cdrh_docs/pdf10/K101935.pdf\"\n          }\n        ]\n      },\n      \"ipdSharingStatementModule\": {\n        \"ipdSharing\": \"UNDECIDED\"\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D012164\",\n            \"term\": \"Retinal Diseases\"\n          },\n          {\n            \"id\": \"D003930\",\n            \"term\": \"Diabetic Retinopathy\"\n          },\n          {\n            \"id\": \"D003922\",\n            \"term\": \"Diabetes Mellitus, Type 1\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D044882\",\n            \"term\": \"Glucose Metabolism Disorders\"\n          },\n          {\n            \"id\": \"D008659\",\n            \"term\": \"Metabolic Diseases\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          },\n          {\n            \"id\": \"D001327\",\n            \"term\": \"Autoimmune Diseases\"\n          },\n          {\n            \"id\": \"D007154\",\n            \"term\": \"Immune System Diseases\"\n          },\n          {\n            \"id\": \"D005128\",\n            \"term\": \"Eye Diseases\"\n          },\n          {\n            \"id\": \"D003925\",\n            \"term\": \"Diabetic Angiopathies\"\n          },\n          {\n            \"id\": \"D014652\",\n            \"term\": \"Vascular Diseases\"\n          },\n          {\n            \"id\": \"D002318\",\n            \"term\": \"Cardiovascular Diseases\"\n          },\n          {\n            \"id\": \"D048909\",\n            \"term\": \"Diabetes Complications\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7117\",\n            \"name\": \"Diabetes Mellitus, Type 1\",\n            \"asFound\": \"Type 1 Diabetes\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M14999\",\n            \"name\": \"Retinal Diseases\",\n            \"asFound\": \"Retinopathy\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7125\",\n            \"name\": \"Diabetic Retinopathy\",\n            \"asFound\": \"Diabetic Retinopathy\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M11639\",\n            \"name\": \"Metabolic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M25403\",\n            \"name\": \"Glucose Metabolism Disorders\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M4629\",\n            \"name\": \"Autoimmune Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M10200\",\n            \"name\": \"Immune System Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M8271\",\n            \"name\": \"Eye Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7120\",\n            \"name\": \"Diabetic Angiopathies\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M17400\",\n            \"name\": \"Vascular Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M26004\",\n            \"name\": \"Diabetes Complications\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          },\n          {\n            \"abbrev\": \"BC20\",\n            \"name\": \"Immune System Diseases\"\n          },\n          {\n            \"abbrev\": \"BC11\",\n            \"name\": \"Eye Diseases\"\n          },\n          {\n            \"abbrev\": \"BC14\",\n            \"name\": \"Heart and Blood Diseases\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT06020846\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"RiphahIU Ume Farva\"\n        },\n        \"organization\": {\n          \"fullName\": \"Riphah International University\",\n          \"class\": \"OTHER\"\n        },\n        \"briefTitle\": \"Effect of Soleus Pushup Exercise in Type 2 Diabetes Patients\",\n        \"officialTitle\": \"Comparison of the Immediate Effects of Soleus Pushup Exercise and Treadmill Walk on Blood Glucose Levels in Type 2 Diabetes Population.\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2024-05\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2023-09-01\",\n          \"type\": \"ACTUAL\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2024-01-30\",\n          \"type\": \"ACTUAL\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2024-02-15\",\n          \"type\": \"ACTUAL\"\n        },\n        \"studyFirstSubmitDate\": \"2023-08-26\",\n        \"studyFirstSubmitQcDate\": \"2023-08-26\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2023-09-01\",\n          \"type\": \"ACTUAL\"\n        },\n        \"lastUpdateSubmitDate\": \"2024-05-19\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2024-05-21\",\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"type\": \"SPONSOR\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"Riphah International University\",\n          \"class\": \"OTHER\"\n        }\n      },\n      \"oversightModule\": {\n        \"oversightHasDmc\": false,\n        \"isFdaRegulatedDrug\": false,\n        \"isFdaRegulatedDevice\": false\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"The aim of this research is to compare the immediate effects of one hour Soleus Pushup Exercise and treadmill walk in Type 2 Diabetic population on blood glucose level. Randomized controlled trials done at Railway General Hospital and diabetic centers of Rawalpindi and Islamabad.. The sample size was 66. The subjects were divided in two groups, 33 subjects in Soleus Pushup Exercise group and 33 subjects in treadmill walk group. Study duration was of 6 months. Sampling technique applied was non probability convenience sampling technique. Only 40-60 years diabetic people with clinically diagnosed type 2 Diabetes for upto 10 years were included. Tools used in the study are Glucometer\",\n        \"detailedDescription\": \"Diabetes is on the rise worldwide, with a global prevalence in adults in 2021 being 537 million adults (20-79 years) living with diabetes -one in ten. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Although physical activity (PA) is a key element in the prevention and management of type 2 diabetes. Structured interventions combining Physical Activity and modest weight loss have been shown to lower type 2 diabetes risk by up to 58% in high-risk populations. The increase in T2DM prevalence can only partly be attributed to the increasing prevalence of obesity and a sedentary lifestyle. The exercise recommendations for individuals with type 2 diabetes are similar as for the general population, suggesting a minimum of 150 min of moderate-vigorous-intensity aerobic exercise each week. However, the general population doesn't adhere to these guidelines.\\n\\nThe goal of treatment in type 2 diabetes is to achieve and maintain optimal BG, lipid, and blood pressure (BP) levels to prevent or delay chronic complications of diabetes. A fundamental principle in exercise physiology is that a small muscle mass working in isolation can achieve a higher local oxygen consumption (VO2/min per kg) than when recruiting a large muscle mass. The soleus (1% body mass) has a highly pennated architecture favoring greater amounts of muscular work during plantarflexion. It has an exceptionally high physiological cross-sectional area (3-8 times more than most of the 20 other limb muscles studied).\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Diabetes Mellitus, Type 2\"\n        ],\n        \"keywords\": [\n          \"diabetes mellitus, type 2\",\n          \"soleus push up\",\n          \"treadmill walk\",\n          \"blood glucose\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"INTERVENTIONAL\",\n        \"phases\": [\n          \"NA\"\n        ],\n        \"designInfo\": {\n          \"allocation\": \"RANDOMIZED\",\n          \"interventionModel\": \"PARALLEL\",\n          \"primaryPurpose\": \"TREATMENT\",\n          \"maskingInfo\": {\n            \"masking\": \"DOUBLE\",\n            \"whoMasked\": [\n              \"PARTICIPANT\",\n              \"OUTCOMES_ASSESSOR\"\n            ]\n          }\n        },\n        \"enrollmentInfo\": {\n          \"count\": 66,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"armsInterventionsModule\": {\n        \"armGroups\": [\n          {\n            \"label\": \"Soleus Pushup Exercise group A\",\n            \"type\": \"EXPERIMENTAL\",\n            \"description\": \"soleus push up exercise\",\n            \"interventionNames\": [\n              \"Other: Soleus Pushup Exercise\"\n            ]\n          },\n          {\n            \"label\": \"Treadmill group 2\",\n            \"type\": \"ACTIVE_COMPARATOR\",\n            \"description\": \"treadmill walk\",\n            \"interventionNames\": [\n              \"Other: treadmill walk group 2\"\n            ]\n          }\n        ],\n        \"interventions\": [\n          {\n            \"type\": \"OTHER\",\n            \"name\": \"Soleus Pushup Exercise\",\n            \"description\": \"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.\\n\\n4 sets of 15 minutes each,1hour total intervention time\",\n            \"armGroupLabels\": [\n              \"Soleus Pushup Exercise group A\"\n            ]\n          },\n          {\n            \"type\": \"OTHER\",\n            \"name\": \"treadmill walk group 2\",\n            \"description\": \"The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time\",\n            \"armGroupLabels\": [\n              \"Treadmill group 2\"\n            ]\n          }\n        ]\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"Blood glucose level\",\n            \"description\": \"The blood glucise level will be measured by the glucometer at base line , 30 min and at 60 min\",\n            \"timeFrame\": \"baseline to 30 minutes and 60 minutes\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* ‚Ä¢ Both male and female individuals\\n\\n  * Individuals with age between 40 to 60 years\\n  * Individuals with clinically diagnosed diabetes type 2 up to 10 years\\n  * individuals not engaged in a structured walking/exercise program\\n  * 2 hours post meal with glucose ranging upto 200.\\n\\nExclusion Criteria:\\n\\n* ‚Ä¢ No recent or planned changes in diet, physical activity, or medications.\\n\\n  * Participants diagnosed with pre-diabetes, gestational diabetes, or type 1 diabetes\",\n        \"healthyVolunteers\": false,\n        \"sex\": \"ALL\",\n        \"minimumAge\": \"40 Years\",\n        \"maximumAge\": \"60 Years\",\n        \"stdAges\": [\n          \"ADULT\"\n        ]\n      },\n      \"contactsLocationsModule\": {\n        \"overallOfficials\": [\n          {\n            \"name\": \"Aisha Razzaq, MSPT-OMPT\",\n            \"affiliation\": \"Riphah International University\",\n            \"role\": \"PRINCIPAL_INVESTIGATOR\"\n          }\n        ],\n        \"locations\": [\n          {\n            \"facility\": \"Railway General Hospital\",\n            \"city\": \"Rawalpindi\",\n            \"state\": \"Punjab\",\n            \"zip\": \"46000\",\n            \"country\": \"Pakistan\",\n            \"geoPoint\": {\n              \"lat\": 33.6007,\n              \"lon\": 73.0679\n            }\n          }\n        ]\n      },\n      \"ipdSharingStatementModule\": {\n        \"ipdSharing\": \"NO\"\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D003924\",\n            \"term\": \"Diabetes Mellitus, Type 2\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D044882\",\n            \"term\": \"Glucose Metabolism Disorders\"\n          },\n          {\n            \"id\": \"D008659\",\n            \"term\": \"Metabolic Diseases\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"asFound\": \"Diabetes Mellitus\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7119\",\n            \"name\": \"Diabetes Mellitus, Type 2\",\n            \"asFound\": \"Diabetes Mellitus, Type 2\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M11639\",\n            \"name\": \"Metabolic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M25403\",\n            \"name\": \"Glucose Metabolism Disorders\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT00395746\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"NN2211-1701\"\n        },\n        \"secondaryIdInfos\": [\n          {\n            \"id\": \"JapicCTI-060324\",\n            \"type\": \"REGISTRY\",\n            \"domain\": \"japic\"\n          }\n        ],\n        \"organization\": {\n          \"fullName\": \"Novo Nordisk A/S\",\n          \"class\": \"INDUSTRY\"\n        },\n        \"briefTitle\": \"Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes\",\n        \"officialTitle\": \"Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2017-01\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2006-10\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2007-10\",\n          \"type\": \"ACTUAL\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2008-05\",\n          \"type\": \"ACTUAL\"\n        },\n        \"studyFirstSubmitDate\": \"2006-11-02\",\n        \"studyFirstSubmitQcDate\": \"2006-11-02\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2006-11-03\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"resultsFirstSubmitDate\": \"2010-02-23\",\n        \"resultsFirstSubmitQcDate\": \"2010-02-23\",\n        \"resultsFirstPostDateStruct\": {\n          \"date\": \"2010-03-12\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"dispFirstSubmitDate\": \"2009-10-26\",\n        \"dispFirstSubmitQcDate\": \"2009-10-26\",\n        \"dispFirstPostDateStruct\": {\n          \"date\": \"2009-10-28\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"lastUpdateSubmitDate\": \"2017-01-25\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2017-03-08\",\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"type\": \"SPONSOR\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"Novo Nordisk A/S\",\n          \"class\": \"INDUSTRY\"\n        }\n      },\n      \"oversightModule\": {\n        \"oversightHasDmc\": false\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed by HbA1c after 24 weeks and 52 weeks in subjects with type 2 diabetes. Liraglutide will be compared to placebo, in combination with SU. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Diabetes\",\n          \"Diabetes Mellitus, Type 2\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"INTERVENTIONAL\",\n        \"phases\": [\n          \"PHASE3\"\n        ],\n        \"designInfo\": {\n          \"allocation\": \"RANDOMIZED\",\n          \"interventionModel\": \"PARALLEL\",\n          \"primaryPurpose\": \"TREATMENT\",\n          \"maskingInfo\": {\n            \"masking\": \"DOUBLE\",\n            \"whoMasked\": [\n              \"PARTICIPANT\",\n              \"INVESTIGATOR\"\n            ]\n          }\n        },\n        \"enrollmentInfo\": {\n          \"count\": 264,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"armsInterventionsModule\": {\n        \"armGroups\": [\n          {\n            \"label\": \"0.6 mg + SU\",\n            \"type\": \"EXPERIMENTAL\",\n            \"description\": \"Liraglutide 0.6 mg + sulphonylurea\",\n            \"interventionNames\": [\n              \"Drug: sulfonylurea\",\n              \"Drug: liraglutide\"\n            ]\n          },\n          {\n            \"label\": \"0.9 mg + SU\",\n            \"type\": \"EXPERIMENTAL\",\n            \"description\": \"Liraglutide 0.9 mg + sulphonylurea\",\n            \"interventionNames\": [\n              \"Drug: sulfonylurea\",\n              \"Drug: liraglutide\"\n            ]\n          },\n          {\n            \"label\": \"SU Mono - 1\",\n            \"type\": \"PLACEBO_COMPARATOR\",\n            \"description\": \"Liraglutide placebo 0.6 mg + sulphonylurea\",\n            \"interventionNames\": [\n              \"Drug: sulfonylurea\"\n            ]\n          },\n          {\n            \"label\": \"SU Mono - 2\",\n            \"type\": \"PLACEBO_COMPARATOR\",\n            \"description\": \"Liraglutide placebo 0.9 mg + sulphonylurea\",\n            \"interventionNames\": [\n              \"Drug: sulfonylurea\"\n            ]\n          }\n        ],\n        \"interventions\": [\n          {\n            \"type\": \"DRUG\",\n            \"name\": \"sulfonylurea\",\n            \"description\": \"SU agent\",\n            \"armGroupLabels\": [\n              \"0.6 mg + SU\",\n              \"0.9 mg + SU\",\n              \"SU Mono - 1\",\n              \"SU Mono - 2\"\n            ]\n          },\n          {\n            \"type\": \"DRUG\",\n            \"name\": \"liraglutide\",\n            \"description\": \"Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.\",\n            \"armGroupLabels\": [\n              \"0.6 mg + SU\"\n            ]\n          },\n          {\n            \"type\": \"DRUG\",\n            \"name\": \"liraglutide\",\n            \"description\": \"Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.\",\n            \"armGroupLabels\": [\n              \"0.9 mg + SU\"\n            ]\n          }\n        ]\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment\",\n            \"timeFrame\": \"after 24 weeks of treatment\"\n          }\n        ],\n        \"secondaryOutcomes\": [\n          {\n            \"measure\": \"Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment\",\n            \"timeFrame\": \"after 52 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Fasting Plasma Glucose After 24 Weeks of Treatment\",\n            \"timeFrame\": \"after 24 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Fasting Plasma Glucose After 52 Weeks of Treatment\",\n            \"timeFrame\": \"after 52 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Postprandial Glucose AUC After 24 Weeks of Treatment\",\n            \"description\": \"Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment\",\n            \"timeFrame\": \"after 24 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Postprandial Glucose AUC After 52 Weeks of Treatment\",\n            \"description\": \"Postprandial Glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment\",\n            \"timeFrame\": \"after 52 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment\",\n            \"description\": \"Plasma glucose (PG) profile measured after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.\",\n            \"timeFrame\": \"after 24 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment\",\n            \"description\": \"7-point plasma glucose (PG) profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.\",\n            \"timeFrame\": \"after 52 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment\",\n            \"description\": \"Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.\",\n            \"timeFrame\": \"after 24 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment\",\n            \"description\": \"Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.\",\n            \"timeFrame\": \"after 52 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Body Weight After 24 Weeks of Treatment\",\n            \"timeFrame\": \"after 24 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Body Weight After 52 Weeks of Treatment\",\n            \"timeFrame\": \"after 52 weeks of treatment\"\n          },\n          {\n            \"measure\": \"Hypoglycaemic Episodes\",\n            \"description\": \"Hypoglycaemic episodes measured over 52 weeks of treatment. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.\",\n            \"timeFrame\": \"over 52 weeks of treatment\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* Type 2 diabetes\\n* Diet/exercise therapy with sulfonylurea (SU) for at least eight weeks\\n* HbA1c greater than or equal to 7.0% and less than 10.0%\\n* BMI less than 35 kg/m2\\n\\nExclusion Criteria:\\n\\n* Treatment with insulin within the last 12 weeks\\n* Treatment with any drug that could interfere with the glucose level\\n* Any serious medical condition\\n* Females who are pregnant, have intention of becoming pregnant or are breastfeeding\",\n        \"healthyVolunteers\": false,\n        \"sex\": \"ALL\",\n        \"minimumAge\": \"20 Years\",\n        \"stdAges\": [\n          \"ADULT\",\n          \"OLDER_ADULT\"\n        ]\n      },\n      \"contactsLocationsModule\": {\n        \"overallOfficials\": [\n          {\n            \"name\": \"Global Clinical Registry (GCR, 1452)\",\n            \"affiliation\": \"Novo Nordisk A/S\",\n            \"role\": \"STUDY_DIRECTOR\"\n          }\n        ],\n        \"locations\": [\n          {\n            \"facility\": \"Novo Nordisk Investigational Site\",\n            \"city\": \"Tokyo\",\n            \"zip\": \"1000005\",\n            \"country\": \"Japan\",\n            \"geoPoint\": {\n              \"lat\": 35.6895,\n              \"lon\": 139.69171\n            }\n          }\n        ]\n      },\n      \"referencesModule\": {\n        \"references\": [\n          {\n            \"pmid\": \"24843595\",\n            \"type\": \"RESULT\",\n            \"citation\": \"Seino Y, Rasmussen MF, Clauson P, Kaku K. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves beta-cell function in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012 Aug 20;3(4):388-95. doi: 10.1111/j.2040-1124.2012.00193.x.\"\n          },\n          {\n            \"pmid\": \"20380655\",\n            \"type\": \"RESULT\",\n            \"citation\": \"Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010 Apr;12(4):341-7. doi: 10.1111/j.1463-1326.2009.01194.x.\"\n          },\n          {\n            \"pmid\": \"23010561\",\n            \"type\": \"RESULT\",\n            \"citation\": \"Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. doi: 10.1016/j.diabres.2012.09.008. Epub 2012 Sep 23.\"\n          },\n          {\n            \"pmid\": \"25504028\",\n            \"type\": \"RESULT\",\n            \"citation\": \"Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12.\"\n          },\n          {\n            \"pmid\": \"21450987\",\n            \"type\": \"DERIVED\",\n            \"citation\": \"Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbaek N, Holst J, Nauck M. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011 Jun;96(6):1695-702. doi: 10.1210/jc.2010-2822. Epub 2011 Mar 30.\"\n          },\n          {\n            \"pmid\": \"21209033\",\n            \"type\": \"DERIVED\",\n            \"citation\": \"Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011 Mar;96(3):853-60. doi: 10.1210/jc.2010-2318. Epub 2011 Jan 5.\"\n          }\n        ],\n        \"seeAlsoLinks\": [\n          {\n            \"label\": \"Clinical Trials at Novo Nordisk\",\n            \"url\": \"http://novonordisk-trials.com\"\n          }\n        ]\n      }\n    },\n    \"resultsSection\": {\n      \"participantFlowModule\": {\n        \"preAssignmentDetails\": \"Subjects included were patients with type 2 diabetes treated with diet therapy and one sulphonylurea (SU) agent (glibenclamide, gliclazide or glimepiride). Subjects continued their current SU therapy with, as a rule, no change in the dose and dosage in the study. A total of 267 subjects were randomised, 3 subjects were not exposed to study drug.\",\n        \"recruitmentDetails\": \"49 sites in Japan\",\n        \"groups\": [\n          {\n            \"id\": \"FG000\",\n            \"title\": \"0.6 mg + SU\",\n            \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n          },\n          {\n            \"id\": \"FG001\",\n            \"title\": \"0.9 mg + SU\",\n            \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n          },\n          {\n            \"id\": \"FG002\",\n            \"title\": \"SU Mono\",\n            \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n          }\n        ],\n        \"periods\": [\n          {\n            \"title\": \"Overall Study\",\n            \"milestones\": [\n              {\n                \"type\": \"STARTED\",\n                \"achievements\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"comment\": \"Exposed to study drug\",\n                    \"numSubjects\": \"88\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"comment\": \"Exposed to study drug\",\n                    \"numSubjects\": \"88\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"comment\": \"Exposed to study drug\",\n                    \"numSubjects\": \"88\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"COMPLETED\",\n                \"achievements\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"comment\": \"Completed 52 weeks treatment\",\n                    \"numSubjects\": \"78\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"comment\": \"Completed 52 weeks treatment\",\n                    \"numSubjects\": \"84\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"comment\": \"Completed 52 weeks treatment\",\n                    \"numSubjects\": \"66\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"NOT COMPLETED\",\n                \"achievements\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"10\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"4\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"22\"\n                  }\n                ]\n              }\n            ],\n            \"dropWithdraws\": [\n              {\n                \"type\": \"Adverse Event\",\n                \"reasons\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"5\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"2\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"2\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"Protocol Violation\",\n                \"reasons\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"1\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"0\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"Lack of Efficacy\",\n                \"reasons\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"2\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"17\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"Hypoglycaemia\",\n                \"reasons\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"2\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"1\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"0\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"Subject decision\",\n                \"reasons\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"1\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"Withdrawal of consent\",\n                \"reasons\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"1\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"Difficultulty in use of device\",\n                \"reasons\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"1\"\n                  }\n                ]\n              },\n              {\n                \"type\": \"Unable to visit site on schedule\",\n                \"reasons\": [\n                  {\n                    \"groupId\": \"FG000\",\n                    \"numSubjects\": \"1\"\n                  },\n                  {\n                    \"groupId\": \"FG001\",\n                    \"numSubjects\": \"0\"\n                  },\n                  {\n                    \"groupId\": \"FG002\",\n                    \"numSubjects\": \"0\"\n                  }\n                ]\n              }\n            ]\n          }\n        ]\n      },\n      \"baselineCharacteristicsModule\": {\n        \"groups\": [\n          {\n            \"id\": \"BG000\",\n            \"title\": \"0.6 mg + SU\",\n            \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n          },\n          {\n            \"id\": \"BG001\",\n            \"title\": \"0.9 mg + SU\",\n            \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n          },\n          {\n            \"id\": \"BG002\",\n            \"title\": \"SU Mono\",\n            \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n          },\n          {\n            \"id\": \"BG003\",\n            \"title\": \"Total\",\n            \"description\": \"Total of all reporting groups\"\n          }\n        ],\n        \"denoms\": [\n          {\n            \"units\": \"Participants\",\n            \"counts\": [\n              {\n                \"groupId\": \"BG000\",\n                \"value\": \"88\"\n              },\n              {\n                \"groupId\": \"BG001\",\n                \"value\": \"88\"\n              },\n              {\n                \"groupId\": \"BG002\",\n                \"value\": \"88\"\n              },\n              {\n                \"groupId\": \"BG003\",\n                \"value\": \"264\"\n              }\n            ]\n          }\n        ],\n        \"measures\": [\n          {\n            \"title\": \"Age, Customized\",\n            \"paramType\": \"NUMBER\",\n            \"unitOfMeasure\": \"participants\",\n            \"classes\": [\n              {\n                \"title\": \"20-29\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"0\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"1\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"0\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"1\"\n                      }\n                    ]\n                  }\n                ]\n              },\n              {\n                \"title\": \"30-39\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"2\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"4\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"0\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"6\"\n                      }\n                    ]\n                  }\n                ]\n              },\n              {\n                \"title\": \"40-49\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"16\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"5\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"19\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"40\"\n                      }\n                    ]\n                  }\n                ]\n              },\n              {\n                \"title\": \"50-59\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"24\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"27\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"28\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"79\"\n                      }\n                    ]\n                  }\n                ]\n              },\n              {\n                \"title\": \"60-69\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"30\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"32\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"30\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"92\"\n                      }\n                    ]\n                  }\n                ]\n              },\n              {\n                \"title\": \"70-\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"16\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"19\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"11\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"46\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ]\n          },\n          {\n            \"title\": \"Age, Continuous\",\n            \"paramType\": \"MEAN\",\n            \"dispersionType\": \"STANDARD_DEVIATION\",\n            \"unitOfMeasure\": \"years\",\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"59.1\",\n                        \"spread\": \"10.3\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"61.3\",\n                        \"spread\": \"11.0\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"58.6\",\n                        \"spread\": \"9.7\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"59.7\",\n                        \"spread\": \"10.4\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ]\n          },\n          {\n            \"title\": \"Sex: Female, Male\",\n            \"paramType\": \"COUNT_OF_PARTICIPANTS\",\n            \"unitOfMeasure\": \"Participants\",\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"title\": \"Female\",\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"35\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"29\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"31\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"95\"\n                      }\n                    ]\n                  },\n                  {\n                    \"title\": \"Male\",\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"53\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"59\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"57\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"169\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ]\n          },\n          {\n            \"title\": \"BMI\",\n            \"description\": \"Body Mass Index\",\n            \"paramType\": \"MEAN\",\n            \"dispersionType\": \"STANDARD_DEVIATION\",\n            \"unitOfMeasure\": \"kg/m2\",\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"25.25\",\n                        \"spread\": \"3.58\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"24.40\",\n                        \"spread\": \"3.37\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"24.94\",\n                        \"spread\": \"3.96\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"24.86\",\n                        \"spread\": \"3.65\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ]\n          },\n          {\n            \"title\": \"Body weight\",\n            \"paramType\": \"MEAN\",\n            \"dispersionType\": \"STANDARD_DEVIATION\",\n            \"unitOfMeasure\": \"kg\",\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"66.19\",\n                        \"spread\": \"12.03\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"64.53\",\n                        \"spread\": \"11.95\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"66.79\",\n                        \"spread\": \"13.66\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"65.84\",\n                        \"spread\": \"12.56\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ]\n          },\n          {\n            \"title\": \"Duration of diabetes\",\n            \"description\": \"Number of years since diagnosis of diabetes\",\n            \"paramType\": \"MEAN\",\n            \"dispersionType\": \"STANDARD_DEVIATION\",\n            \"unitOfMeasure\": \"years\",\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"9.33\",\n                        \"spread\": \"5.77\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"11.61\",\n                        \"spread\": \"7.68\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"10.06\",\n                        \"spread\": \"7.28\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"10.33\",\n                        \"spread\": \"7.00\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ]\n          },\n          {\n            \"title\": \"HbA1c\",\n            \"description\": \"Glycosylated Haemoglobin\",\n            \"paramType\": \"MEAN\",\n            \"dispersionType\": \"STANDARD_DEVIATION\",\n            \"unitOfMeasure\": \"percentage of total haemoglobin\",\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"BG000\",\n                        \"value\": \"8.48\",\n                        \"spread\": \"0.73\"\n                      },\n                      {\n                        \"groupId\": \"BG001\",\n                        \"value\": \"8.26\",\n                        \"spread\": \"0.71\"\n                      },\n                      {\n                        \"groupId\": \"BG002\",\n                        \"value\": \"8.44\",\n                        \"spread\": \"0.83\"\n                      },\n                      {\n                        \"groupId\": \"BG003\",\n                        \"value\": \"8.39\",\n                        \"spread\": \"0.76\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ]\n          }\n        ]\n      },\n      \"outcomeMeasuresModule\": {\n        \"outcomeMeasures\": [\n          {\n            \"type\": \"PRIMARY\",\n            \"title\": \"Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"percentage of total haemoglobin\",\n            \"timeFrame\": \"after 24 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"86\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"87\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"88\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"7.02\",\n                        \"spread\": \"0.10\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"6.75\",\n                        \"spread\": \"0.11\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"8.02\",\n                        \"spread\": \"0.10\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and HbA1C at baseline as a covariate. Two null hypotheses were statistically tested:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively. When the test of comparison between 0.9 mg+SU and SU mono was significant, the test of comparison between 0.6 mg+SU and SU mono was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"pValueComment\": \"A significance level of a two-sided 5% was used for statistical hypothesis testing.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-1.27\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-1.51\",\n                \"ciUpperLimit\": \"1.02\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and HbA1C at baseline as a covariate. Two null hypotheses were statistically tested:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively. When the test of comparison between 0.9 mg+SU and SU mono was significant, the test of comparison between 0.6 mg+SU and SU mono was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"statisticalComment\": \"A significance level of a two-sided 5% was used for statistical hypothesis testing.\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-1.00\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-1.24\",\n                \"ciUpperLimit\": \"-0.75\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"percentage of total haemoglobin\",\n            \"timeFrame\": \"after 52 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"86\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"87\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"88\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"7.42\",\n                        \"spread\": \"0.12\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"7.06\",\n                        \"spread\": \"0.13\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"8.39\",\n                        \"spread\": \"0.12\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-1.33\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-1.62\",\n                \"ciUpperLimit\": \"-1.04\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-0.96\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-1.25\",\n                \"ciUpperLimit\": \"-0.67\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Fasting Plasma Glucose After 24 Weeks of Treatment\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"mg/dL\",\n            \"timeFrame\": \"after 24 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"85\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"86\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"87\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"132.2\",\n                        \"spread\": \"3.5\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"126.2\",\n                        \"spread\": \"3.5\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"158.8\",\n                        \"spread\": \"3.5\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%: H10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-32.4\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-40.5\",\n                \"ciUpperLimit\": \"-24.2\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%: H10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-26.4\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-34.5\",\n                \"ciUpperLimit\": \"-18.2\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Fasting Plasma Glucose After 52 Weeks of Treatment\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"mg/dL\",\n            \"timeFrame\": \"after 52 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"85\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"86\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"87\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"140.3\",\n                        \"spread\": \"4.0\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"134.5\",\n                        \"spread\": \"4.1\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"164.6\",\n                        \"spread\": \"4.0\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-30.2\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-39.6\",\n                \"ciUpperLimit\": \"-20.7\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-24.4\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-33.8\",\n                \"ciUpperLimit\": \"-14.9\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Postprandial Glucose AUC After 24 Weeks of Treatment\",\n            \"description\": \"Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"mg/dL *h\",\n            \"timeFrame\": \"after 24 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"83\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"84\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"71\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"614.58\",\n                        \"spread\": \"14.75\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"575.50\",\n                        \"spread\": \"15.01\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"725.72\",\n                        \"spread\": \"15.71\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-150.22\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-186.32\",\n                \"ciUpperLimit\": \"-114.12\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-111.15\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-147.61\",\n                \"ciUpperLimit\": \"-74.68\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Postprandial Glucose AUC After 52 Weeks of Treatment\",\n            \"description\": \"Postprandial Glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"mg/dL *h\",\n            \"timeFrame\": \"after 52 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"78\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"83\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"68\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"648.87\",\n                        \"spread\": \"16.09\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"589.98\",\n                        \"spread\": \"16.17\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"717.55\",\n                        \"spread\": \"17.08\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-127.57\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-166.91\",\n                \"ciUpperLimit\": \"-88.24\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-68.68\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-108.91\",\n                \"ciUpperLimit\": \"-28.45\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment\",\n            \"description\": \"Plasma glucose (PG) profile measured after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"mg/dL\",\n            \"timeFrame\": \"after 24 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"80\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"82\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"80\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"160.20\",\n                        \"spread\": \"4.44\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"150.05\",\n                        \"spread\": \"4.56\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"194.50\",\n                        \"spread\": \"4.61\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-44.45\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-55.02\",\n                \"ciUpperLimit\": \"-33.89\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-34.30\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-45.06\",\n                \"ciUpperLimit\": \"-23.54\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment\",\n            \"description\": \"7-point plasma glucose (PG) profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"mg/dL\",\n            \"timeFrame\": \"after 52 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"81\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"80\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"82\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"171.42\",\n                        \"spread\": \"5.11\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"159.58\",\n                        \"spread\": \"5.30\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"205.92\",\n                        \"spread\": \"5.25\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-34.49\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-46.77\",\n                \"ciUpperLimit\": \"-22.22\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-46.34\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-58.49\",\n                \"ciUpperLimit\": \"-34.18\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment\",\n            \"description\": \"Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"mg/dL\",\n            \"timeFrame\": \"after 24 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"81\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"82\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"82\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"86.38\",\n                        \"spread\": \"4.65\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"68.34\",\n                        \"spread\": \"4.78\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"79.71\",\n                        \"spread\": \"4.75\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"0.0433\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-11.37\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-22.40\",\n                \"ciUpperLimit\": \"-0.34\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"0.2359\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"6.67\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-4.39\",\n                \"ciUpperLimit\": \"17.73\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment\",\n            \"description\": \"Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"mg/dL\",\n            \"timeFrame\": \"after 52 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"82\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"80\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"85\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"82.28\",\n                        \"spread\": \"4.81\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"76.09\",\n                        \"spread\": \"5.00\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"89.39\",\n                        \"spread\": \"4.86\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-13.30\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-24.69\",\n                \"ciUpperLimit\": \"-1.90\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"-7.11\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"-18.42\",\n                \"ciUpperLimit\": \"4.21\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Body Weight After 24 Weeks of Treatment\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"kg\",\n            \"timeFrame\": \"after 24 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"87\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"87\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"88\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"65.77\",\n                        \"spread\": \"0.23\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"65.34\",\n                        \"spread\": \"0.24\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"64.59\",\n                        \"spread\": \"0.23\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"0.0071\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"0.75\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.21\",\n                \"ciUpperLimit\": \"1.30\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected at a significance level of 5%:\\n\\nH10: Œº0.9 = ŒºSU, H11: Œº0.9 ‚â† ŒºSU H20: Œº0.6 = ŒºSU, H21: Œº0.6 ‚â† ŒºSU where Œº0.6, Œº0.9 and ŒºSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"pValue\": \"<0.0001\",\n                \"pValueComment\": \"To perform the pairwise comparisons simultaneously, a closed testing procedure was applied. When the hypothesis Œº0.9 = Œº0.6 = ŒºSU was rejected, the 2 hypotheses of pairwise comparison were tested simultaneously both at significance level of 5%.\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"1.18\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.63\",\n                \"ciUpperLimit\": \"1.73\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Body Weight After 52 Weeks of Treatment\",\n            \"populationDescription\": \"Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all subjects who received at least one dose of study drug and have valid measurements both at baseline and at least one time point after baseline.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"LEAST_SQUARES_MEAN\",\n            \"dispersionType\": \"Standard Error\",\n            \"unitOfMeasure\": \"kg\",\n            \"timeFrame\": \"after 52 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"87\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"87\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"88\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"65.96\",\n                        \"spread\": \"0.26\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"65.87\",\n                        \"spread\": \"0.27\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"64.83\",\n                        \"spread\": \"0.26\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"1.04\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.42\",\n                \"ciUpperLimit\": \"1.66\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"95% confidence interval for the mean difference (each liraglutide - SU monotherapy) was calculated under an analysis of variance (ANOVA) model with treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate, and no statistical testing was performed\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"ANOVA\",\n                \"paramType\": \"Least Squares Mean\",\n                \"paramValue\": \"1.13\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.51\",\n                \"ciUpperLimit\": \"1.75\"\n              }\n            ]\n          },\n          {\n            \"type\": \"SECONDARY\",\n            \"title\": \"Hypoglycaemic Episodes\",\n            \"description\": \"Hypoglycaemic episodes measured over 52 weeks of treatment. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.\",\n            \"populationDescription\": \"Full Analysis Set (FAS) consists of all subjects who received at least one dose of study drug.\",\n            \"reportingStatus\": \"POSTED\",\n            \"paramType\": \"NUMBER\",\n            \"unitOfMeasure\": \"number of events per year of exposure\",\n            \"timeFrame\": \"over 52 weeks of treatment\",\n            \"groups\": [\n              {\n                \"id\": \"OG000\",\n                \"title\": \"0.6 mg + SU\",\n                \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG001\",\n                \"title\": \"0.9 mg + SU\",\n                \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              },\n              {\n                \"id\": \"OG002\",\n                \"title\": \"SU Mono\",\n                \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\"\n              }\n            ],\n            \"denoms\": [\n              {\n                \"units\": \"Participants\",\n                \"counts\": [\n                  {\n                    \"groupId\": \"OG000\",\n                    \"value\": \"88\"\n                  },\n                  {\n                    \"groupId\": \"OG001\",\n                    \"value\": \"88\"\n                  },\n                  {\n                    \"groupId\": \"OG002\",\n                    \"value\": \"88\"\n                  }\n                ]\n              }\n            ],\n            \"classes\": [\n              {\n                \"title\": \"All hypoglycaemic episodes\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"3.131\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"3.715\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"2.990\"\n                      }\n                    ]\n                  }\n                ]\n              },\n              {\n                \"title\": \"Major\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"0.0000\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"0.0000\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"0.0000\"\n                      }\n                    ]\n                  }\n                ]\n              },\n              {\n                \"title\": \"Minor\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"1.438\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"1.365\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"1.285\"\n                      }\n                    ]\n                  }\n                ]\n              },\n              {\n                \"title\": \"Symptoms only\",\n                \"categories\": [\n                  {\n                    \"measurements\": [\n                      {\n                        \"groupId\": \"OG000\",\n                        \"value\": \"1.693\"\n                      },\n                      {\n                        \"groupId\": \"OG001\",\n                        \"value\": \"2.350\"\n                      },\n                      {\n                        \"groupId\": \"OG002\",\n                        \"value\": \"1.705\"\n                      }\n                    ]\n                  }\n                ]\n              }\n            ],\n            \"analyses\": [\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"The relative risk for 'All hypoglycaemic episodes' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"Negative binomial regression\",\n                \"paramType\": \"Rate ratio\",\n                \"paramValue\": \"1.59\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.86\",\n                \"ciUpperLimit\": \"2.96\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"The relative risk for 'Minor episodes' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"Negative binomial regression model\",\n                \"paramType\": \"Rate ratio\",\n                \"paramValue\": \"1.18\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.56\",\n                \"ciUpperLimit\": \"2.47\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG001\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"The relative risk for 'Symptoms only' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"Negative binomial regression model\",\n                \"paramType\": \"Rate ratio\",\n                \"paramValue\": \"1.80\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.92\",\n                \"ciUpperLimit\": \"3.54\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"The relative risk for 'All hypoglycaemic episodes' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"Negative binomial regression model\",\n                \"paramType\": \"Rate ratio\",\n                \"paramValue\": \"1.62\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.85\",\n                \"ciUpperLimit\": \"3.07\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"The relative risk for 'Minor episodes' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"Negative binomial regression model\",\n                \"paramType\": \"Rate ratio\",\n                \"paramValue\": \"1.48\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.69\",\n                \"ciUpperLimit\": \"3.17\"\n              },\n              {\n                \"groupIds\": [\n                  \"OG000\",\n                  \"OG002\"\n                ],\n                \"groupDescription\": \"The relative risk for 'Symptoms only episodes' and 95% confidence interval are based on a generalised linear negative-binomial model, which included treatment group as a fixed effect and log of exposure time as an offset variable.\",\n                \"nonInferiorityType\": \"SUPERIORITY_OR_OTHER\",\n                \"statisticalMethod\": \"Negative binomial regression model\",\n                \"paramType\": \"Rate ratio\",\n                \"paramValue\": \"1.45\",\n                \"ciPctValue\": \"95\",\n                \"ciLowerLimit\": \"0.72\",\n                \"ciUpperLimit\": \"2.91\"\n              }\n            ]\n          }\n        ]\n      },\n      \"adverseEventsModule\": {\n        \"frequencyThreshold\": \"5\",\n        \"timeFrame\": \"Adverse events were collected in a time span over 52 weeks.\",\n        \"description\": \"The safety analysis population consists of all subjects exposed to study drug (Full Analysis Set, FAS).\",\n        \"eventGroups\": [\n          {\n            \"id\": \"EG000\",\n            \"title\": \"0.6 mg + SU\",\n            \"description\": \"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\",\n            \"seriousNumAffected\": 4,\n            \"seriousNumAtRisk\": 88,\n            \"otherNumAffected\": 68,\n            \"otherNumAtRisk\": 88\n          },\n          {\n            \"id\": \"EG001\",\n            \"title\": \"0.9 mg + SU\",\n            \"description\": \"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\",\n            \"seriousNumAffected\": 3,\n            \"seriousNumAtRisk\": 88,\n            \"otherNumAffected\": 68,\n            \"otherNumAtRisk\": 88\n          },\n          {\n            \"id\": \"EG002\",\n            \"title\": \"SU Mono\",\n            \"description\": \"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment\",\n            \"seriousNumAffected\": 5,\n            \"seriousNumAtRisk\": 88,\n            \"otherNumAffected\": 59,\n            \"otherNumAtRisk\": 88\n          }\n        ],\n        \"seriousEvents\": [\n          {\n            \"term\": \"Sudden hearing loss\",\n            \"organSystem\": \"Ear and labyrinth disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Colitis ischaemic\",\n            \"organSystem\": \"Gastrointestinal disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Cholecystitis\",\n            \"organSystem\": \"Hepatobiliary disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Bursitis infective\",\n            \"organSystem\": \"Infections and infestations\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Pneumonia\",\n            \"organSystem\": \"Infections and infestations\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Hyperglycaemia\",\n            \"organSystem\": \"Metabolism and nutrition disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Spinal osteoarthritis\",\n            \"organSystem\": \"Musculoskeletal and connective tissue disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Benign neoplasm of skin\",\n            \"organSystem\": \"Neoplasms benign, malignant and unspecified (incl cysts and polyps)\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Colon adenoma\",\n            \"organSystem\": \"Neoplasms benign, malignant and unspecified (incl cysts and polyps)\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Oesophageal carcinoma\",\n            \"organSystem\": \"Neoplasms benign, malignant and unspecified (incl cysts and polyps)\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Epiglottic cyst\",\n            \"organSystem\": \"Respiratory, thoracic and mediastinal disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Cataract operation\",\n            \"organSystem\": \"Surgical and medical procedures\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              }\n            ]\n          }\n        ],\n        \"otherEvents\": [\n          {\n            \"term\": \"Nasopharyngitis\",\n            \"organSystem\": \"Infections and infestations\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 63,\n                \"numAffected\": 37,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 51,\n                \"numAffected\": 38,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 61,\n                \"numAffected\": 35,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Diarrhoea\",\n            \"organSystem\": \"Gastrointestinal disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 8,\n                \"numAffected\": 7,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 17,\n                \"numAffected\": 14,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 10,\n                \"numAffected\": 7,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Constipation\",\n            \"organSystem\": \"Gastrointestinal disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 9,\n                \"numAffected\": 8,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 12,\n                \"numAffected\": 11,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 7,\n                \"numAffected\": 4,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Dental caries\",\n            \"organSystem\": \"Gastrointestinal disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 5,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 5,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Gastritis\",\n            \"organSystem\": \"Gastrointestinal disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 3,\n                \"numAffected\": 3,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 4,\n                \"numAffected\": 4,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 8,\n                \"numAffected\": 8,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Back pain\",\n            \"organSystem\": \"Musculoskeletal and connective tissue disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 10,\n                \"numAffected\": 10,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 8,\n                \"numAffected\": 7,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 6,\n                \"numAffected\": 6,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Arthralgia\",\n            \"organSystem\": \"Musculoskeletal and connective tissue disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 6,\n                \"numAffected\": 6,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 3,\n                \"numAffected\": 3,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Diabetic retinopathy\",\n            \"organSystem\": \"Eye disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 8,\n                \"numAffected\": 8,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 11,\n                \"numAffected\": 11,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 7,\n                \"numAffected\": 7,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Dizziness\",\n            \"organSystem\": \"Nervous system disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 7,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 7,\n                \"numAffected\": 6,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 2,\n                \"numAffected\": 2,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Headache\",\n            \"organSystem\": \"Nervous system disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 11,\n                \"numAffected\": 10,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 4,\n                \"numAffected\": 4,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 9,\n                \"numAffected\": 8,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Hypoaesthesia\",\n            \"organSystem\": \"Nervous system disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 6,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 0,\n                \"numAffected\": 0,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 5,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Alanine aminotransferase increased\",\n            \"organSystem\": \"Investigations\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 7,\n                \"numAffected\": 6,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 2,\n                \"numAffected\": 2,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 1,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Malaise\",\n            \"organSystem\": \"General disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 6,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 2,\n                \"numAffected\": 1,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 6,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Upper respiratory tract inflammation\",\n            \"organSystem\": \"Respiratory, thoracic and mediastinal disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 12,\n                \"numAffected\": 9,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 8,\n                \"numAffected\": 6,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 5,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Fall\",\n            \"organSystem\": \"Injury, poisoning and procedural complications\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 5,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 3,\n                \"numAffected\": 2,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 2,\n                \"numAffected\": 2,\n                \"numAtRisk\": 88\n              }\n            ]\n          },\n          {\n            \"term\": \"Hypertension\",\n            \"organSystem\": \"Vascular disorders\",\n            \"sourceVocabulary\": \"MedDRA (11.0)\",\n            \"assessmentType\": \"SYSTEMATIC_ASSESSMENT\",\n            \"stats\": [\n              {\n                \"groupId\": \"EG000\",\n                \"numEvents\": 5,\n                \"numAffected\": 5,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG001\",\n                \"numEvents\": 3,\n                \"numAffected\": 3,\n                \"numAtRisk\": 88\n              },\n              {\n                \"groupId\": \"EG002\",\n                \"numEvents\": 5,\n                \"numAffected\": 4,\n                \"numAtRisk\": 88\n              }\n            ]\n          }\n        ]\n      },\n      \"moreInfoModule\": {\n        \"certainAgreement\": {\n          \"piSponsorEmployee\": false,\n          \"restrictionType\": \"OTHER\",\n          \"restrictiveAgreement\": true,\n          \"otherDetails\": \"Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.\"\n        },\n        \"pointOfContact\": {\n          \"title\": \"Public Access to Clinical Trials\",\n          \"organization\": \"Novo Nordisk A/S\",\n          \"email\": \"clinicaltrials@novonordisk.com\"\n        }\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D003924\",\n            \"term\": \"Diabetes Mellitus, Type 2\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D044882\",\n            \"term\": \"Glucose Metabolism Disorders\"\n          },\n          {\n            \"id\": \"D008659\",\n            \"term\": \"Metabolic Diseases\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"asFound\": \"Diabetes\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7119\",\n            \"name\": \"Diabetes Mellitus, Type 2\",\n            \"asFound\": \"Diabetes Mellitus, Type 2\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M11639\",\n            \"name\": \"Metabolic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M25403\",\n            \"name\": \"Glucose Metabolism Disorders\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          }\n        ]\n      },\n      \"interventionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D000069450\",\n            \"term\": \"Liraglutide\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D000097789\",\n            \"term\": \"Glucagon-Like Peptide-1 Receptor Agonists\"\n          },\n          {\n            \"id\": \"D007004\",\n            \"term\": \"Hypoglycemic Agents\"\n          },\n          {\n            \"id\": \"D045505\",\n            \"term\": \"Physiological Effects of Drugs\"\n          },\n          {\n            \"id\": \"D054795\",\n            \"term\": \"Incretins\"\n          },\n          {\n            \"id\": \"D006728\",\n            \"term\": \"Hormones\"\n          },\n          {\n            \"id\": \"D006730\",\n            \"term\": \"Hormones, Hormone Substitutes, and Hormone Antagonists\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M419\",\n            \"name\": \"Liraglutide\",\n            \"asFound\": \"Syringe\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M3401\",\n            \"name\": \"Glucagon-Like Peptide-1 Receptor Agonists\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M9043\",\n            \"name\": \"Glucagon\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M26997\",\n            \"name\": \"Glucagon-Like Peptide 1\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M10054\",\n            \"name\": \"Hypoglycemic Agents\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M27905\",\n            \"name\": \"Incretins\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M9789\",\n            \"name\": \"Hormones\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M9788\",\n            \"name\": \"Hormone Antagonists\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"Hypo\",\n            \"name\": \"Hypoglycemic Agents\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Drugs and Chemicals\"\n          },\n          {\n            \"abbrev\": \"Gast\",\n            \"name\": \"Gastrointestinal Agents\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": true\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT01299246\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"98-2224-B\"\n        },\n        \"organization\": {\n          \"fullName\": \"Chang Gung Memorial Hospital\",\n          \"class\": \"OTHER\"\n        },\n        \"briefTitle\": \"The Effectiveness of Improving Self-care After Counseling for the Diabetics Mellitus Foots Around Chiayi Region\",\n        \"officialTitle\": \"The Effectiveness of Improving Self-care and Health Status After Promoting Counseling for the Diabetics Mellitus Patients With DM Foots Around Yunlin and Chiayi Region\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2009-10\",\n        \"overallStatus\": \"UNKNOWN\",\n        \"lastKnownStatus\": \"ACTIVE_NOT_RECRUITING\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2009-11\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2012-11\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2013-07\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"studyFirstSubmitDate\": \"2011-01-30\",\n        \"studyFirstSubmitQcDate\": \"2011-02-17\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2011-02-18\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"lastUpdateSubmitDate\": \"2011-02-17\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2011-02-18\",\n          \"type\": \"ESTIMATED\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"oldNameTitle\": \"Chang Gung Memorial Hospital\",\n          \"oldOrganization\": \"Chang Gung Memorial Hospital\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"Chang Gung Memorial Hospital\",\n          \"class\": \"OTHER\"\n        }\n      },\n      \"oversightModule\": {\n        \"oversightHasDmc\": true\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"Objectives:\\n\\nPreventing diabetic foot problems (DFP) and associated consequences, such as amputation, is a critical in rural regions. The objective is to present on the association of non-invasive DFP assessment tools and physiological indicators for the early detection of DFP among rural cases of diabetes in Taiwan.\",\n        \"detailedDescription\": \"1. Peripheral neurological assessment was carried out using Michigan Neuropathy Screening Instrument (MNSI). The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet (normal/abnormal with 0 and 1 point); if abnormal, then inspection of lower limbs for deformities, dry skin, fissure, calluses or infection was carried out; (2) Identification of foot ulceration (yes/no with 0 and 1 point); (3) Vibration perception of the big toe (present/decreased/absent, with 0, 0,5 and 1 points); (4) Ankle reflexes (present/reinforcement/absent, with 0, 0,5 and 1 points); (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament (normal/reduced/absent, with 0, 0,5 and 1 points). When an MNSI summative score was ‚â•2 points with neuropathy, patients were referred to the teaching hospitals for further evaluation. The MNSI procedures took 6-8 minutes for each participant.\\n2. Peripheral vascular assessment: three parameters were used to assess peripheral vascular function by trained nurses. (a) The Cardio-Vision Model MS-2000 was used to detect Ankle Brachial Index (ABI), assessed by research nurses. Values of ABI were classified as ‚â•0.9 normal and \\\\<0.9 abnormal. (b) Palpable pedal, posterior tibias and popliteal pulses were recorded as absent, weak or present. (c) Capillary refill time was done by pressing the tip of the toenail for two seconds, and taking the time for the blanched area to turn pink again. If the return time took \\\\>2 seconds, this was taken as ischemia. Assessing of all 3 parameters of peripheral vascular assessment took 10-15 minutes for each participant.\\n3. Diabetic foot risk assessment was assessed by plastic surgeons: (a) King's College classification (KC) contained six stages of condition: not at risk, at risk, ulcer, cellulites, necrosis and amputation. (b) the Texas risk classification (TRC) system was divided into six categories in origin. We re-categorized three levels: low risk, at risk, and high risk.\\n4. The blood glucose, total cholesterol, and low density of lipoprotein cholesterol were drawn from the last 1-2 month diabetes passport record for each subject. Blood pressure was measured according to standard procedures by the nurses during the study. Body mass index was calculated for each participant using the standard formula (weight in kilograms divided by square of the height in meters). Waist circumference in centimeter was used to measure central obesity, measuring the mid-abdominal distance between the last rib margin and the iliac crest.\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Diabetic Foot\",\n          \"Type 2 Diabetes Mellitus With Established Diabetic Nephropathy\"\n        ],\n        \"keywords\": [\n          \"Diabetic Foot\",\n          \"non-invasive DFP assessment tools\",\n          \"early detection of DFP\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"INTERVENTIONAL\",\n        \"phases\": [\n          \"PHASE1\",\n          \"PHASE2\"\n        ],\n        \"designInfo\": {\n          \"allocation\": \"RANDOMIZED\",\n          \"interventionModel\": \"SINGLE_GROUP\",\n          \"primaryPurpose\": \"SCREENING\",\n          \"maskingInfo\": {\n            \"masking\": \"SINGLE\",\n            \"whoMasked\": [\n              \"PARTICIPANT\"\n            ]\n          }\n        },\n        \"enrollmentInfo\": {\n          \"count\": 386,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"armsInterventionsModule\": {\n        \"armGroups\": [\n          {\n            \"label\": \"improving self-care\",\n            \"type\": \"EXPERIMENTAL\",\n            \"interventionNames\": [\n              \"Procedure: Michigan Neuropathy Screening Instrument\"\n            ]\n          }\n        ],\n        \"interventions\": [\n          {\n            \"type\": \"PROCEDURE\",\n            \"name\": \"Michigan Neuropathy Screening Instrument\",\n            \"description\": \"Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.\",\n            \"armGroupLabels\": [\n              \"improving self-care\"\n            ],\n            \"otherNames\": [\n              \"Cardio-Vision Model MS-2000 for ABI measurement.\"\n            ]\n          }\n        ]\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"Number of the residents in detecting the early neurovasculopathy\",\n            \"description\": \"It is shown that using the MNSI and ABI as community screening tools can be useful in detecting the early neurovasculopathy for diabetic rural residents. In addition, where an ABI machine is unavailable, performing MNSI using primary healthcare providers might be cost-effective.\",\n            \"timeFrame\": \"1 year\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* diabetics mellitus patients\",\n        \"healthyVolunteers\": true,\n        \"sex\": \"ALL\",\n        \"stdAges\": [\n          \"CHILD\",\n          \"ADULT\",\n          \"OLDER_ADULT\"\n        ]\n      },\n      \"contactsLocationsModule\": {\n        \"overallOfficials\": [\n          {\n            \"name\": \"Mei-Yen Chen, Ph.D.\",\n            \"affiliation\": \"Graduate Institute of Nursing, Chang Gung Institute of Technology, Chiayi Campus, Taiwan. Tel: 886 (5) 3628800 ext. 2201, Fax: 886-5-3628866, Email: meiyen@gw.cgit.edu.tw\",\n            \"role\": \"STUDY_CHAIR\"\n          }\n        ],\n        \"locations\": [\n          {\n            \"facility\": \"Graduate Institute of Nursing, Chang Gung Institute of Technology, Chiayi Campus\",\n            \"city\": \"Chiayi\",\n            \"zip\": \"61363\",\n            \"country\": \"Taiwan\"\n          }\n        ]\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D003928\",\n            \"term\": \"Diabetic Nephropathies\"\n          },\n          {\n            \"id\": \"D017719\",\n            \"term\": \"Diabetic Foot\"\n          },\n          {\n            \"id\": \"D003924\",\n            \"term\": \"Diabetes Mellitus, Type 2\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D044882\",\n            \"term\": \"Glucose Metabolism Disorders\"\n          },\n          {\n            \"id\": \"D008659\",\n            \"term\": \"Metabolic Diseases\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          },\n          {\n            \"id\": \"D007674\",\n            \"term\": \"Kidney Diseases\"\n          },\n          {\n            \"id\": \"D014570\",\n            \"term\": \"Urologic Diseases\"\n          },\n          {\n            \"id\": \"D052776\",\n            \"term\": \"Female Urogenital Diseases\"\n          },\n          {\n            \"id\": \"D005261\",\n            \"term\": \"Female Urogenital Diseases and Pregnancy Complications\"\n          },\n          {\n            \"id\": \"D000091642\",\n            \"term\": \"Urogenital Diseases\"\n          },\n          {\n            \"id\": \"D052801\",\n            \"term\": \"Male Urogenital Diseases\"\n          },\n          {\n            \"id\": \"D003925\",\n            \"term\": \"Diabetic Angiopathies\"\n          },\n          {\n            \"id\": \"D014652\",\n            \"term\": \"Vascular Diseases\"\n          },\n          {\n            \"id\": \"D002318\",\n            \"term\": \"Cardiovascular Diseases\"\n          },\n          {\n            \"id\": \"D016523\",\n            \"term\": \"Foot Ulcer\"\n          },\n          {\n            \"id\": \"D007871\",\n            \"term\": \"Leg Ulcer\"\n          },\n          {\n            \"id\": \"D012883\",\n            \"term\": \"Skin Ulcer\"\n          },\n          {\n            \"id\": \"D012871\",\n            \"term\": \"Skin Diseases\"\n          },\n          {\n            \"id\": \"D048909\",\n            \"term\": \"Diabetes Complications\"\n          },\n          {\n            \"id\": \"D003929\",\n            \"term\": \"Diabetic Neuropathies\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M10698\",\n            \"name\": \"Kidney Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7119\",\n            \"name\": \"Diabetes Mellitus, Type 2\",\n            \"asFound\": \"Type 2 Diabetes Mellitus\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M19933\",\n            \"name\": \"Diabetic Foot\",\n            \"asFound\": \"Diabetic Foot\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7123\",\n            \"name\": \"Diabetic Nephropathies\",\n            \"asFound\": \"Diabetic Nephropathy\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M11639\",\n            \"name\": \"Metabolic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M25403\",\n            \"name\": \"Glucose Metabolism Disorders\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M17319\",\n            \"name\": \"Urologic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M2875\",\n            \"name\": \"Urogenital Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M27093\",\n            \"name\": \"Female Urogenital Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M14127\",\n            \"name\": \"Pregnancy Complications\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M8399\",\n            \"name\": \"Female Urogenital Diseases and Pregnancy Complications\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M27095\",\n            \"name\": \"Male Urogenital Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7120\",\n            \"name\": \"Diabetic Angiopathies\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M17400\",\n            \"name\": \"Vascular Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M17206\",\n            \"name\": \"Ulcer\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M18919\",\n            \"name\": \"Foot Ulcer\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M10883\",\n            \"name\": \"Leg Ulcer\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M15686\",\n            \"name\": \"Skin Ulcer\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M15674\",\n            \"name\": \"Skin Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M26004\",\n            \"name\": \"Diabetes Complications\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7124\",\n            \"name\": \"Diabetic Neuropathies\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          },\n          {\n            \"abbrev\": \"BXS\",\n            \"name\": \"Urinary Tract, Sexual Organs, and Pregnancy Conditions\"\n          },\n          {\n            \"abbrev\": \"BC14\",\n            \"name\": \"Heart and Blood Diseases\"\n          },\n          {\n            \"abbrev\": \"BC17\",\n            \"name\": \"Skin and Connective Tissue Diseases\"\n          },\n          {\n            \"abbrev\": \"BC23\",\n            \"name\": \"Symptoms and General Pathology\"\n          },\n          {\n            \"abbrev\": \"BC10\",\n            \"name\": \"Nervous System Diseases\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT06941246\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"P-ME-24-04\"\n        },\n        \"organization\": {\n          \"fullName\": \"Faculty of Dental Medicine for Girls\",\n          \"class\": \"OTHER_GOV\"\n        },\n        \"briefTitle\": \"Prolactin Levels in Type 2 Diabetic Patients With Stage III Periodontitis\",\n        \"officialTitle\": \"Gingival Crevicular Fluid Levels of Prolactin Hormone in Type 2 Diabetic Patients With Stage III Periodontitis Before and After Non-Surgical Treatments\",\n        \"acronym\": \"prolactin\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2025-04\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2024-10-01\",\n          \"type\": \"ACTUAL\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2025-01-01\",\n          \"type\": \"ACTUAL\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2025-04-01\",\n          \"type\": \"ACTUAL\"\n        },\n        \"studyFirstSubmitDate\": \"2025-04-12\",\n        \"studyFirstSubmitQcDate\": \"2025-04-19\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2025-04-23\",\n          \"type\": \"ACTUAL\"\n        },\n        \"lastUpdateSubmitDate\": \"2025-04-19\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2025-04-23\",\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"type\": \"PRINCIPAL_INVESTIGATOR\",\n          \"investigatorFullName\": \"Sara Ibrahim\",\n          \"investigatorTitle\": \"master's degree student at oral medicine, peridontology ,oral diagnosis and oral Radiology Department, faculty of Dental Medicine for Girls ,Al Azhar university\",\n          \"investigatorAffiliation\": \"Faculty of Dental Medicine for Girls\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"Faculty of Dental Medicine for Girls\",\n          \"class\": \"OTHER_GOV\"\n        }\n      },\n      \"oversightModule\": {\n        \"oversightHasDmc\": false,\n        \"isFdaRegulatedDrug\": false,\n        \"isFdaRegulatedDevice\": false\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"evaluate the role of prolactin hormone in the pathogenesis of periodontitis by assessing its local gingival levels and assess clinical parameters in patients who have type two diabetes\",\n        \"detailedDescription\": \"Periodontal Examination At baseline, all participants received a full-mouth clinical examination, and the following periodontal parameters will be recorded: Plaque Index (PI) (19), Gingival Index (GI) (20), Pocket Depth (PD), and Clinical Attachment Loss (CAL).\\n\\nInitial periodontal examination, full mouth scaling and root planning (SRP), clinical measurements before and after treatment, gingival crevicular fluid sampling as well as reinforcement of oral hygiene at baseline and during follow-up evaluations will be performed by the same periodontist (E.A.). Reinforcement of oral hygiene will be done every month for 3 months.\\n\\nGingival fluid sampling:\\n\\nGingival crevicular fluid (GCF) collection will be done the second day after clinical examination to prevent the contamination of sample with blood associated with the probing of inflamed sites. Samples will be collected from the buccal aspects of two interproximal sites in teeth that had the highest signs of inflammation and attachment loss for periodontitis groups, this will be done before, and 3 months after SRP. For the control group, samples will be collected from the upper first molar.\\n\\nThe samples will be assayed for PRL by using an enzyme linked immunosorbent assay (ELISA) kits.\\n\\nPatient's examinations:\\n\\nGlycosylated Hemoglobin (Hemoglobin A1c) test and Body Mass Index will be measured to all participants.\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Type 2 Diabetes Mellitus\"\n        ],\n        \"keywords\": [\n          \"Diabetes Mellitus ,Type 2\",\n          \"periodontitis\",\n          \"Gingival Crevicular Fluid\",\n          \"Prolactin\",\n          \"Non- surgical periodontal treatment\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"INTERVENTIONAL\",\n        \"phases\": [\n          \"NA\"\n        ],\n        \"designInfo\": {\n          \"allocation\": \"RANDOMIZED\",\n          \"interventionModel\": \"PARALLEL\",\n          \"interventionModelDescription\": \"Periodontal Examination At baseline, all participants received a full-mouth clinical examination, and the following periodontal parameters will be recorded: Plaque Index (PI) (19), Gingival Index (GI) (20), Pocket Depth (PD), and Clinical Attachment Loss (CAL).\\n\\nInitial periodontal examination, full mouth scaling and root planning (SRP), clinical measurements before and after treatment, gingival crevicular fluid sampling as well as reinforcement of oral hygiene at baseline and during follow-up evaluations will be performed by the same periodontist (E.A.). Reinforcement of oral hygiene will be done every month for 3 months.\\n\\nGingival fluid sampling:\\n\\nGingival crevicular fluid (GCF) collection will be done the second day after clinical examination to prevent the contamination of sample with blood associated with the probing of inflamed sites. Samples will be collected from the buccal aspects of two interproximal sites in teeth that had the highest signs of inflammation and attachment loss\",\n          \"primaryPurpose\": \"TREATMENT\",\n          \"maskingInfo\": {\n            \"masking\": \"NONE\"\n          }\n        },\n        \"enrollmentInfo\": {\n          \"count\": 80,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"armsInterventionsModule\": {\n        \"armGroups\": [\n          {\n            \"label\": \"Healthy (control).\",\n            \"type\": \"OTHER\",\n            \"description\": \"a full-mouth clinical examination, and the following periodontal parameters will be recorded: Plaque Index (PI) (19), Gingival Index (GI) (20), Pocket Depth (PD), and Clinical Attachment Loss (CAL).Gingival fluid sampling: Gingival crevicular fluid (GCF) collection will be done the second day after clinical examination to prevent the contamination of sample with blood associated with the probing of inflamed sites. Samples will be collected from the buccal aspects of two interproximal sites in teeth that had the highest signs of inflammation and attachment loss for periodontitis groups, this will be done before, and 3 months after SRP. For the control group, samples will be collected from the upper first molar.\\n\\nThe samples will be assayed for PRL by using an enzyme linked immunosorbent assay (ELISA) kits.\",\n            \"interventionNames\": [\n              \"Device: paper points\",\n              \"Device: ELISA Kits\"\n            ]\n          },\n          {\n            \"label\": \"Stage III periodontitis without diabetes\",\n            \"type\": \"ACTIVE_COMPARATOR\",\n            \"description\": \"Periodontal Examination At baseline, all participants received a full-mouth clinical examination, and the following periodontal parameters will be recorded: Plaque Index (PI) (19), Gingival Index (GI) (20), Pocket Depth (PD), and Clinical Attachment Loss (CAL).\\n\\nInitial periodontal examination, full mouth scaling and root planning (SRP), clinical measurements before and after treatment, gingival crevicular fluid sampling as well as reinforcement of oral hygiene at baseline and during follow-up evaluations will be performed by the same periodontist (E.A.). Reinforcement of oral hygiene will be done every month for 3 months.\\n\\nGingival fluid sampling:\\n\\nGingival crevicular fluid (GCF) collection will be done the second day after clinical examination to prevent the contamination of sample with blood associated with the probing of inflamed sites.\",\n            \"interventionNames\": [\n              \"Procedure: Non Surgical Periodontal Treatment\",\n              \"Device: paper points\",\n              \"Device: ELISA Kits\"\n            ]\n          },\n          {\n            \"label\": \"Stage III periodontitis with controlled type 2 diabetes\",\n            \"type\": \"ACTIVE_COMPARATOR\",\n            \"description\": \"Periodontal Examination At baseline, all participants received a full-mouth clinical examination, and the following periodontal parameters will be recorded: Plaque Index (PI) (19), Gingival Index (GI) (20), Pocket Depth (PD), and Clinical Attachment Loss (CAL).\\n\\nInitial periodontal examination, full mouth scaling and root planning (SRP), clinical measurements before and after treatment, gingival crevicular fluid sampling as well as reinforcement of oral hygiene at baseline and during follow-up evaluations will be performed by the same periodontist (E.A.). Reinforcement of oral hygiene will be done every month for 3 months.\\n\\nGingival fluid sampling:\\n\\nSamples will be collected from the buccal aspects of two interproximal sites in teeth that had the highest signs of inflammation and attachment loss\",\n            \"interventionNames\": [\n              \"Procedure: Non Surgical Periodontal Treatment\",\n              \"Device: paper points\",\n              \"Device: ELISA Kits\"\n            ]\n          },\n          {\n            \"label\": \"Stage III periodontitis with uncontrolled type 2 diabetes\",\n            \"type\": \"ACTIVE_COMPARATOR\",\n            \"description\": \"Periodontal Examination At baseline, all participants received a full-mouth clinical examination, and the following periodontal parameters will be recorded: Plaque Index (PI) (19), Gingival Index (GI) (20), Pocket Depth (PD), and Clinical Attachment Loss (CAL).\\n\\nInitial periodontal examination, full mouth scaling and root planning (SRP), clinical measurements before and after treatment, gingival crevicular fluid sampling as well as reinforcement of oral hygiene at baseline and during follow-up evaluations will be performed by the same periodontist (E.A.). Reinforcement of oral hygiene will be done every month for 3 months.\\n\\nGingival fluid sampling:\\n\\nSamples will be collected from the buccal aspects of two interproximal sites in teeth that had the highest signs of inflammation and attachment loss\",\n            \"interventionNames\": [\n              \"Procedure: Non Surgical Periodontal Treatment\",\n              \"Device: paper points\",\n              \"Device: ELISA Kits\"\n            ]\n          }\n        ],\n        \"interventions\": [\n          {\n            \"type\": \"PROCEDURE\",\n            \"name\": \"Non Surgical Periodontal Treatment\",\n            \"description\": \"the intervention includes Non Surgical Periodontal Therapy( scaling and root planning ),performed to reduce periodontal inflammation .Gingival Crevicular fluid samples will be collected before and after treatment to assess changes in prolactin hormone levels.\",\n            \"armGroupLabels\": [\n              \"Stage III periodontitis with controlled type 2 diabetes\",\n              \"Stage III periodontitis with uncontrolled type 2 diabetes\",\n              \"Stage III periodontitis without diabetes\"\n            ]\n          },\n          {\n            \"type\": \"DEVICE\",\n            \"name\": \"paper points\",\n            \"description\": \"we use paper point to collect GCF sample\",\n            \"armGroupLabels\": [\n              \"Healthy (control).\",\n              \"Stage III periodontitis with controlled type 2 diabetes\",\n              \"Stage III periodontitis with uncontrolled type 2 diabetes\",\n              \"Stage III periodontitis without diabetes\"\n            ]\n          },\n          {\n            \"type\": \"DEVICE\",\n            \"name\": \"ELISA Kits\",\n            \"description\": \"The samples are analyzed by ELISA kits to measure prolactin levels\",\n            \"armGroupLabels\": [\n              \"Healthy (control).\",\n              \"Stage III periodontitis with controlled type 2 diabetes\",\n              \"Stage III periodontitis with uncontrolled type 2 diabetes\",\n              \"Stage III periodontitis without diabetes\"\n            ]\n          }\n        ]\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"Change in Prolactin Hormone Levels in Gingival Crevicular Fluid\",\n            \"description\": \"Gingival crevicular fluid (GCF) will be collected to measure prolactin hormone levels using enzyme-linked immunosorbent assay (ELISA) kits. Samples will be taken from the buccal aspects of two interproximal sites in each participant. Baseline and post-treatment samples will be collected and analyzed. Higher prolactin levels may be associated with more severe inflammation. Unit of Measure :ng/mL\",\n            \"timeFrame\": \"Baseline and 3 months after non-surgical periodontal treatment\"\n          }\n        ],\n        \"secondaryOutcomes\": [\n          {\n            \"measure\": \"Change in Plaque Index (PI)\",\n            \"description\": \"The Plaque Index will be measured using the Silness and L√∂e Index. Scores range from 0 (no plaque) to 3 (abundant plaque on tooth surface). Higher scores indicate worse oral hygiene.reinforcement of oral hygiene at baseline and during follow-up evaluations will be performed by the same periodontist (E.A.). Reinforcement of oral hygiene will be done every month for 3 months. Higher scores indicate worse oral hygiene. Unit of measure: PI Score (0-3)\",\n            \"timeFrame\": \"Baseline and 3 months after treatment\"\n          },\n          {\n            \"measure\": \"Change in Gingival Index (GI)\",\n            \"description\": \"The Gingival Index will be evaluated using the L√∂e and Silness method. Scores range from 0 (normal gingiva) to 3 (severe inflammation with spontaneous bleeding). Higher scores indicate worse gingival condition. Unit of measure: GI Score (0-3).\",\n            \"timeFrame\": \"Baseline and 3 months after treatment\"\n          },\n          {\n            \"measure\": \"Change in Probing Depth (PD)\",\n            \"description\": \"Probing depth will be measured using a periodontal probe at selected sites. Measurements are recorded in millimeters. Greater probing depth indicates more advanced periodontal destruction. Unit of measure: millimeters (mm)\",\n            \"timeFrame\": \"Baseline and 3 months after treatment\"\n          },\n          {\n            \"measure\": \"Change in Clinical Attachment Level (CAL)\",\n            \"description\": \"Clinical attachment level will be assessed using a periodontal probe to determine the extent of periodontal support loss. Higher values indicate greater tissue damage. Higher values indicate worse periodontal condition Unit of measure: millimeters (mm)\",\n            \"timeFrame\": \"Baseline and 3 months after treatment\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* Age range from 18 to 60 years\\n* Stage III periodontitis\\n* Type 2 diabetes\\n* Only patients signing informed written consents\\n\\nExclusion Criteria:\\n\\n* Pregnancy or lactation\\n* Any known systemic disease\\n* Any type of previous periodontal treatment (surgical or non-surgical) in the preceding 6 months\\n* Smoking (former or current)\",\n        \"healthyVolunteers\": true,\n        \"sex\": \"ALL\",\n        \"minimumAge\": \"18 Years\",\n        \"maximumAge\": \"60 Years\",\n        \"stdAges\": [\n          \"ADULT\"\n        ]\n      },\n      \"contactsLocationsModule\": {\n        \"overallOfficials\": [\n          {\n            \"name\": \"Naglaa El wakeel, Professer\",\n            \"affiliation\": \"Al-Azhar University\",\n            \"role\": \"STUDY_DIRECTOR\"\n          },\n          {\n            \"name\": \"Zahraa Saeed, lecturer\",\n            \"affiliation\": \"Al-Azhar University\",\n            \"role\": \"STUDY_DIRECTOR\"\n          },\n          {\n            \"name\": \"Olfat shaker, profeser\",\n            \"affiliation\": \"Cairo University\",\n            \"role\": \"STUDY_DIRECTOR\"\n          }\n        ],\n        \"locations\": [\n          {\n            \"facility\": \"Sara Ibrahim Hussein Eid\",\n            \"city\": \"Cairo\",\n            \"zip\": \"12345\",\n            \"country\": \"Egypt\",\n            \"geoPoint\": {\n              \"lat\": 30.06263,\n              \"lon\": 31.24967\n            }\n          }\n        ]\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D010518\",\n            \"term\": \"Periodontitis\"\n          },\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D003924\",\n            \"term\": \"Diabetes Mellitus, Type 2\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D044882\",\n            \"term\": \"Glucose Metabolism Disorders\"\n          },\n          {\n            \"id\": \"D008659\",\n            \"term\": \"Metabolic Diseases\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          },\n          {\n            \"id\": \"D010510\",\n            \"term\": \"Periodontal Diseases\"\n          },\n          {\n            \"id\": \"D009059\",\n            \"term\": \"Mouth Diseases\"\n          },\n          {\n            \"id\": \"D009057\",\n            \"term\": \"Stomatognathic Diseases\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"asFound\": \"Diabetes Mellitus\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M13427\",\n            \"name\": \"Periodontitis\",\n            \"asFound\": \"Periodontitis\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7119\",\n            \"name\": \"Diabetes Mellitus, Type 2\",\n            \"asFound\": \"Type 2 Diabetes Mellitus\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M11639\",\n            \"name\": \"Metabolic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M25403\",\n            \"name\": \"Glucose Metabolism Disorders\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M13419\",\n            \"name\": \"Periodontal Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M12019\",\n            \"name\": \"Mouth Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M12017\",\n            \"name\": \"Stomatognathic Diseases\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          },\n          {\n            \"abbrev\": \"BC07\",\n            \"name\": \"Mouth and Tooth Diseases\"\n          }\n        ]\n      },\n      \"interventionBrowseModule\": {\n        \"browseLeaves\": [\n          {\n            \"id\": \"M9789\",\n            \"name\": \"Hormones\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Drugs and Chemicals\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT03138746\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"R20160801\"\n        },\n        \"organization\": {\n          \"fullName\": \"University of Adelaide\",\n          \"class\": \"OTHER\"\n        },\n        \"briefTitle\": \"Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric Air\",\n        \"officialTitle\": \"Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric Air\",\n        \"acronym\": \"HOTAIR4\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2020-11\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2018-08-13\",\n          \"type\": \"ACTUAL\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2020-01-15\",\n          \"type\": \"ACTUAL\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2020-01-15\",\n          \"type\": \"ACTUAL\"\n        },\n        \"studyFirstSubmitDate\": \"2017-05-01\",\n        \"studyFirstSubmitQcDate\": \"2017-05-01\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2017-05-03\",\n          \"type\": \"ACTUAL\"\n        },\n        \"lastUpdateSubmitDate\": \"2020-11-02\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2020-11-04\",\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"type\": \"PRINCIPAL_INVESTIGATOR\",\n          \"investigatorFullName\": \"A/Prof Leonie Heilbronn\",\n          \"investigatorTitle\": \"ARC Future Fellow\",\n          \"investigatorAffiliation\": \"University of Adelaide\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"University of Adelaide\",\n          \"class\": \"OTHER\"\n        },\n        \"collaborators\": [\n          {\n            \"name\": \"Royal Adelaide Hospital\",\n            \"class\": \"OTHER\"\n          }\n        ]\n      },\n      \"oversightModule\": {\n        \"oversightHasDmc\": false,\n        \"isFdaRegulatedDrug\": false,\n        \"isFdaRegulatedDevice\": false\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"In a recent series of studies performed by our group, we have shown that exposure to hyperbaric oxygen (HBO) leads to an increase in insulin sensitivity in male subjects with type-2 diabetes (T2DM) and in obese and overweight men without diabetes. The aim of this study is to investigate the relationship between pressure and oxygen in producing this effect, specifically, is this effect measurable in hyperbaric air or is some higher pressure of oxygen required?\\n\\nAims:\\n\\n1. To determine whether the insulin sensitising effect of HBO is apparent in hyperbaric air at the same pressure as HBO.\\n2. To examine mechanisms underpinning the increase in insulin sensitivity following HBO.\",\n        \"detailedDescription\": \"The 40 participants will be randomly allocated to two groups, matched for BMI. All participants will attend the Hyperbaric Medicine Unit on 2 occasions and metabolic testing will be undertaken at the same time of the day. Day 1 will be for baseline assessment sitting outside the hyperbaric chamber. Day 2 will be two days after Day 1 in the same week during which participants will undergo a 2-hour session in the hyperbaric chamber with a \\\"10:90:30\\\" compression profile (compression of the chamber in air to 2 atmospheres absolute, then donning a \\\"hood\\\" supplying high flow gas for 90-minutes followed by a linear decompression back to 1 atmosphere absolute over 30-minutes). Half of the participants will breathe oxygen during this compression profile while the other half will breathe medical air.\\n\\nAn overnight fast (10-hours) will be required prior to each day with modification of their diabetic medication. This regimen will be monitored in consultation with a diabetes specialist (IC):\\n\\n* If prescribed metformin, withhold the evening dose before each study day but give other usual evening oral drugs\\n* If taking evening insulin, reduce dose to 2/3 of usual dose the night before each study day\\n* Hold diabetes drugs (oral or injectable) on morning of study until conclusion of study and then administer with food. Take usual morning oral medication at this time and modified insulin dose (if prescribed insulin)\\n* Check BSL on arrival and departure each study day\\n\\nDay 1. Baseline assessment. The participant will attend at 0900 for a hyperinsulinaemic euglycaemic clamp, which will be performed with the same protocol as used in our three previous clamp studies. Two intravenous cannulae are inserted into veins in contralateral forearms using local anaesthetic (lignocaine 1%). Baseline blood is taken for fasting glucose and insulin and a primed insulin infusion is started (80mU/m2/min) for 3¬Ω hours. Blood samples (\\\\<2mls) are obtained at 5-10 minute intervals so that blood glucose can be maintained at 5.5 mmol/L with a variable infusion of 25% Dextrose and a trained individual will be present for the duration of the clamping procedure. Insulin sensitivity will be assessed by the steady state glucose infusion rate calculated over a stable 30-minute period of the clamp. Assessments will be made at two points during the 3¬Ω hour clamp; at 2¬Ω-3 hours and 3-3¬Ω hours. Immediately post-clamp, volunteers are given orange juice and high carbohydrate lunch, and the glucose infusion is maintained on halving scale for 5 minutes each for at least 20 minutes. Blood sugar levels are monitored every 10-15 minutes for 60 minutes. Total blood taken during the clamping procedure will be less than 100mls including baseline samples. The researchers have performed several hundred clamps.\\n\\nDay 2. The participant will attend at 0900 for a second 3¬Ω-hour hyperinsulinaemic euglycaemic clamp, similar to Day1. The procedure for the two groups (HBO and hyperbaric air) will be identical, the only difference will be the breathing gas used during the 10:90:30 hyperbaric exposures. The breathing gas delivered to the participant (oxygen or air) will be supplied from masked \\\"research\\\" gas outlets, so the participant will be blinded as to which group they are in. The participant will enter the chamber after a 1-hour clamp stabilising period and assessment of the steady state glucose infusion rate will take place at similar times to Day1. This means that during the 2-hour hyperbaric exposure, the assessment periods will correspond to the 30-minute decompression at the end of the hyperbaric session and the first 30-minutes after exit from the hyperbaric chamber. Post clamp will be managed as during Day1.\\n\\nBlood samples (20 ml) for inflammatory markers will be taken before and after procedures on both days. With blood taken during 2 clamps (less than 100mls each) and four 20 ml samples, total blood taken will be approximately 280 ml.\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Diabetes Mellitus, Type II\",\n          \"Insulin Resistance\"\n        ],\n        \"keywords\": [\n          \"hyperbaric oxygenation\",\n          \"insulin sensitivity\",\n          \"human\",\n          \"inflammation\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"OBSERVATIONAL\",\n        \"patientRegistry\": false,\n        \"designInfo\": {\n          \"observationalModel\": \"COHORT\",\n          \"timePerspective\": \"PROSPECTIVE\"\n        },\n        \"bioSpec\": {\n          \"retention\": \"SAMPLES_WITHOUT_DNA\",\n          \"description\": \"Serum\"\n        },\n        \"enrollmentInfo\": {\n          \"count\": 25,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"armsInterventionsModule\": {\n        \"armGroups\": [\n          {\n            \"label\": \"HBO\",\n            \"description\": \"On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing 100% oxygen\",\n            \"interventionNames\": [\n              \"Procedure: HBO\"\n            ]\n          },\n          {\n            \"label\": \"Hyperbaric air\",\n            \"description\": \"On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing air\",\n            \"interventionNames\": [\n              \"Procedure: Hyperbaric air\"\n            ]\n          }\n        ],\n        \"interventions\": [\n          {\n            \"type\": \"PROCEDURE\",\n            \"name\": \"HBO\",\n            \"description\": \"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a \\\"hood\\\" supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes\",\n            \"armGroupLabels\": [\n              \"HBO\"\n            ]\n          },\n          {\n            \"type\": \"PROCEDURE\",\n            \"name\": \"Hyperbaric air\",\n            \"description\": \"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a \\\"hood\\\" supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes\",\n            \"armGroupLabels\": [\n              \"Hyperbaric air\"\n            ]\n          }\n        ]\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"insulin sensitivity\",\n            \"description\": \"As measured by the glucose infusion rate during the steady-state phase of the hyperinsulinaemic euglycaemic clamp on day 2\",\n            \"timeFrame\": \"Baseline to Day 2\"\n          }\n        ],\n        \"secondaryOutcomes\": [\n          {\n            \"measure\": \"change in inflammatory cytokines\",\n            \"description\": \"analysis of serum inflammatory markers pre and post procedures on Days 1 and 2\",\n            \"timeFrame\": \"Day 1 and 2\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* Men with T2DM, n=40 (numbers are based on power analysis of previous studies)\\n* Normal to obese weight (BMI 25-40 kg/m2)\\n* Age \\\\> 40 (no specific upper age limit)\\n* All participants will attend the Hyperbaric Medicine Unit to be assessed by a hyperbaric physician (DW) to determine fitness to enter the hyperbaric chamber the standard clinical criteria of the Hyperbaric Medicine Unit will be used\\n\\nExclusion Criteria:\\n\\n* use of prescribed or non-prescribed medications which may affect glucose homeostasis (eg steroids)\\n* uncontrolled asthma, current fever, upper respiratory infections\\n* individuals who regularly perform high intensity exercise (\\\\>2 week)\\n* current intake of \\\\> 140g alcohol/week\\n* current smokers of cigarettes/cigars/marijuana\\n* current intake of any illicit substance\\n* experience claustrophobia in confined spaces\\n* has donated blood within past 3-months\\n* has been involved in any other study within the past 3-months\\n* unable to comprehend study protocol\\n* any other contraindication to HBO (eg Eustachian tube dysfunction making middle ear inflation ineffective)\",\n        \"healthyVolunteers\": false,\n        \"sex\": \"MALE\",\n        \"minimumAge\": \"40 Years\",\n        \"stdAges\": [\n          \"ADULT\",\n          \"OLDER_ADULT\"\n        ],\n        \"studyPopulation\": \"Community sample\",\n        \"samplingMethod\": \"NON_PROBABILITY_SAMPLE\"\n      },\n      \"contactsLocationsModule\": {\n        \"overallOfficials\": [\n          {\n            \"name\": \"David C Wilkinson, FANZCA\",\n            \"affiliation\": \"University of Adelaide\",\n            \"role\": \"PRINCIPAL_INVESTIGATOR\"\n          }\n        ],\n        \"locations\": [\n          {\n            \"facility\": \"Hyperbaric Medicine Unit, Royal Adelaide Hospital\",\n            \"city\": \"Adelaide\",\n            \"state\": \"South Australia\",\n            \"zip\": \"5000\",\n            \"country\": \"Australia\",\n            \"geoPoint\": {\n              \"lat\": -34.92866,\n              \"lon\": 138.59863\n            }\n          }\n        ]\n      },\n      \"referencesModule\": {\n        \"references\": [\n          {\n            \"pmid\": \"22269009\",\n            \"type\": \"BACKGROUND\",\n            \"citation\": \"Wilkinson D, Chapman IM, Heilbronn LK. Hyperbaric oxygen therapy improves peripheral insulin sensitivity in humans. Diabet Med. 2012 Aug;29(8):986-9. doi: 10.1111/j.1464-5491.2012.03587.x.\"\n          },\n          {\n            \"pmid\": \"25964036\",\n            \"type\": \"BACKGROUND\",\n            \"citation\": \"Wilkinson D, Nolting M, Mahadi MK, Chapman I, Heilbronn L. Hyperbaric oxygen therapy increases insulin sensitivity in overweight men with and without type 2 diabetes. Diving Hyperb Med. 2015 Mar;45(1):30-6.\"\n          }\n        ]\n      },\n      \"ipdSharingStatementModule\": {\n        \"ipdSharing\": \"NO\"\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D007333\",\n            \"term\": \"Insulin Resistance\"\n          },\n          {\n            \"id\": \"D003924\",\n            \"term\": \"Diabetes Mellitus, Type 2\"\n          },\n          {\n            \"id\": \"D006967\",\n            \"term\": \"Hypersensitivity\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D044882\",\n            \"term\": \"Glucose Metabolism Disorders\"\n          },\n          {\n            \"id\": \"D008659\",\n            \"term\": \"Metabolic Diseases\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          },\n          {\n            \"id\": \"D007154\",\n            \"term\": \"Immune System Diseases\"\n          },\n          {\n            \"id\": \"D006946\",\n            \"term\": \"Hyperinsulinism\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M10018\",\n            \"name\": \"Hypersensitivity\",\n            \"asFound\": \"Sensitivity\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M10293\",\n            \"name\": \"Inflammation\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M10370\",\n            \"name\": \"Insulin Resistance\",\n            \"asFound\": \"Insulin Sensitivity\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7119\",\n            \"name\": \"Diabetes Mellitus, Type 2\",\n            \"asFound\": \"Diabetes Mellitus, Type II\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M11639\",\n            \"name\": \"Metabolic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M25403\",\n            \"name\": \"Glucose Metabolism Disorders\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M10200\",\n            \"name\": \"Immune System Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M9997\",\n            \"name\": \"Hyperinsulinism\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC20\",\n            \"name\": \"Immune System Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          },\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"BC23\",\n            \"name\": \"Symptoms and General Pathology\"\n          }\n        ]\n      },\n      \"interventionBrowseModule\": {\n        \"browseLeaves\": [\n          {\n            \"id\": \"M10365\",\n            \"name\": \"Insulin\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M173166\",\n            \"name\": \"Insulin, Globin Zinc\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"Hypo\",\n            \"name\": \"Hypoglycemic Agents\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Drugs and Chemicals\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT01821846\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"NN2211-3929\"\n        },\n        \"secondaryIdInfos\": [\n          {\n            \"id\": \"U1111-1132-2221\",\n            \"type\": \"OTHER\",\n            \"domain\": \"WHO\"\n          }\n        ],\n        \"organization\": {\n          \"fullName\": \"Novo Nordisk A/S\",\n          \"class\": \"INDUSTRY\"\n        },\n        \"briefTitle\": \"Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus\",\n        \"officialTitle\": \"A 6-month, Multi-centre, Open Labelled, Non-randomized, Non-interventional, Safety Study of Liraglutide (Victoza¬Æ) in Subjects With Type 2 Diabetes Mellitus in Korea\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2017-08\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2013-11-20\",\n          \"type\": \"ACTUAL\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2017-03-08\",\n          \"type\": \"ACTUAL\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2017-03-08\",\n          \"type\": \"ACTUAL\"\n        },\n        \"studyFirstSubmitDate\": \"2013-03-27\",\n        \"studyFirstSubmitQcDate\": \"2013-03-29\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2013-04-01\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"lastUpdateSubmitDate\": \"2017-08-18\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2017-08-21\",\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"type\": \"SPONSOR\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"Novo Nordisk A/S\",\n          \"class\": \"INDUSTRY\"\n        }\n      },\n      \"oversightModule\": {\n        \"oversightHasDmc\": false\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza¬Æ) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Diabetes\",\n          \"Diabetes Mellitus, Type 2\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"OBSERVATIONAL\",\n        \"patientRegistry\": false,\n        \"designInfo\": {\n          \"observationalModel\": \"COHORT\",\n          \"timePerspective\": \"PROSPECTIVE\"\n        },\n        \"enrollmentInfo\": {\n          \"count\": 64,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"armsInterventionsModule\": {\n        \"armGroups\": [\n          {\n            \"label\": \"Liraglutide\",\n            \"interventionNames\": [\n              \"Drug: liraglutide\"\n            ]\n          }\n        ],\n        \"interventions\": [\n          {\n            \"type\": \"DRUG\",\n            \"name\": \"liraglutide\",\n            \"description\": \"Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).\",\n            \"armGroupLabels\": [\n              \"Liraglutide\"\n            ]\n          }\n        ]\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"The incidence of SADRs (Serious Adverse Drug Reactions)\",\n            \"timeFrame\": \"Up to 6 months\"\n          }\n        ],\n        \"secondaryOutcomes\": [\n          {\n            \"measure\": \"HbA1c (Glycosylated haemoglobin) change\",\n            \"timeFrame\": \"Month 0, month 6\"\n          },\n          {\n            \"measure\": \"Percentage of subjects reaching the target of HbA1c below 7.0%\",\n            \"timeFrame\": \"Month 6\"\n          },\n          {\n            \"measure\": \"Change in body weight\",\n            \"timeFrame\": \"Month 0, month 6\"\n          },\n          {\n            \"measure\": \"Number of SAEs/ ADRs (Serious Adverse Events/Adverse Drug Reactions)\",\n            \"timeFrame\": \"Up to 6 months\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* Subjects with T2DM (Type 2 Diabetes Mellitus), including newly-diagnosed subjects, who require treatment with Victoza¬Æ according to the clinical judgment of their treating physician\\n* Subjects (and/or parents or the subject's legally acceptable representative) who are capable of giving study-specific signed informed consent before any collection of information\\n\\nExclusion Criteria:\\n\\n* Subjects with a hypersensitivity to Victoza¬Æ or to any of the excipients\\n* Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods\\n* Subjects with personal or family history of medullary thyroid carcinoma (MTC)\\n* Subjects with multiple endocrine neoplasia syndrome type 2 (MEN2)\",\n        \"healthyVolunteers\": false,\n        \"sex\": \"ALL\",\n        \"stdAges\": [\n          \"CHILD\",\n          \"ADULT\",\n          \"OLDER_ADULT\"\n        ],\n        \"studyPopulation\": \"Victoza¬Æ will be prescribed and titrated by the physician.\",\n        \"samplingMethod\": \"NON_PROBABILITY_SAMPLE\"\n      },\n      \"contactsLocationsModule\": {\n        \"overallOfficials\": [\n          {\n            \"name\": \"Global Clinical Registry (GCR, 1452)\",\n            \"affiliation\": \"Novo Nordisk A/S\",\n            \"role\": \"STUDY_DIRECTOR\"\n          }\n        ],\n        \"locations\": [\n          {\n            \"facility\": \"Novo Nordisk Investigational Site\",\n            \"city\": \"Pyungchon-Dong 896, Dongan-Gu\",\n            \"zip\": \"431-796\",\n            \"country\": \"Korea, Republic of\"\n          },\n          {\n            \"facility\": \"Novo Nordisk Investigational Site\",\n            \"city\": \"Seoul\",\n            \"zip\": \"02447\",\n            \"country\": \"Korea, Republic of\",\n            \"geoPoint\": {\n              \"lat\": 37.566,\n              \"lon\": 126.9784\n            }\n          },\n          {\n            \"facility\": \"Novo Nordisk Investigational Site\",\n            \"city\": \"Seoul\",\n            \"zip\": \"03080\",\n            \"country\": \"Korea, Republic of\",\n            \"geoPoint\": {\n              \"lat\": 37.566,\n              \"lon\": 126.9784\n            }\n          },\n          {\n            \"facility\": \"Novo Nordisk Investigational Site\",\n            \"city\": \"Seoul\",\n            \"zip\": \"150-950\",\n            \"country\": \"Korea, Republic of\",\n            \"geoPoint\": {\n              \"lat\": 37.566,\n              \"lon\": 126.9784\n            }\n          },\n          {\n            \"facility\": \"Novo Nordisk Investigational Site\",\n            \"city\": \"Ulsan\",\n            \"zip\": \"44455\",\n            \"country\": \"Korea, Republic of\",\n            \"geoPoint\": {\n              \"lat\": 35.53722,\n              \"lon\": 129.31667\n            }\n          },\n          {\n            \"facility\": \"Novo Nordisk Investigational Site\",\n            \"city\": \"Ulsan\",\n            \"zip\": \"682-060\",\n            \"country\": \"Korea, Republic of\",\n            \"geoPoint\": {\n              \"lat\": 35.53722,\n              \"lon\": 129.31667\n            }\n          },\n          {\n            \"facility\": \"Novo Nordisk Investigational Site\",\n            \"city\": \"Wonju\",\n            \"zip\": \"220-701\",\n            \"country\": \"Korea, Republic of\",\n            \"geoPoint\": {\n              \"lat\": 37.35139,\n              \"lon\": 127.94528\n            }\n          }\n        ]\n      },\n      \"referencesModule\": {\n        \"seeAlsoLinks\": [\n          {\n            \"label\": \"Clinical Trials at Novo Nordisk\",\n            \"url\": \"http://novonordisk-trials.com\"\n          }\n        ]\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D003924\",\n            \"term\": \"Diabetes Mellitus, Type 2\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D044882\",\n            \"term\": \"Glucose Metabolism Disorders\"\n          },\n          {\n            \"id\": \"D008659\",\n            \"term\": \"Metabolic Diseases\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"asFound\": \"Diabetes Mellitus\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7119\",\n            \"name\": \"Diabetes Mellitus, Type 2\",\n            \"asFound\": \"Diabetes Mellitus, Type 2\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M11639\",\n            \"name\": \"Metabolic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M25403\",\n            \"name\": \"Glucose Metabolism Disorders\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          }\n        ]\n      },\n      \"interventionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D000069450\",\n            \"term\": \"Liraglutide\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D000097789\",\n            \"term\": \"Glucagon-Like Peptide-1 Receptor Agonists\"\n          },\n          {\n            \"id\": \"D007004\",\n            \"term\": \"Hypoglycemic Agents\"\n          },\n          {\n            \"id\": \"D045505\",\n            \"term\": \"Physiological Effects of Drugs\"\n          },\n          {\n            \"id\": \"D054795\",\n            \"term\": \"Incretins\"\n          },\n          {\n            \"id\": \"D006728\",\n            \"term\": \"Hormones\"\n          },\n          {\n            \"id\": \"D006730\",\n            \"term\": \"Hormones, Hormone Substitutes, and Hormone Antagonists\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M419\",\n            \"name\": \"Liraglutide\",\n            \"asFound\": \"Syringe\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M3401\",\n            \"name\": \"Glucagon-Like Peptide-1 Receptor Agonists\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M9043\",\n            \"name\": \"Glucagon\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M26997\",\n            \"name\": \"Glucagon-Like Peptide 1\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M10054\",\n            \"name\": \"Hypoglycemic Agents\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M27905\",\n            \"name\": \"Incretins\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M9789\",\n            \"name\": \"Hormones\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M9788\",\n            \"name\": \"Hormone Antagonists\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"Hypo\",\n            \"name\": \"Hypoglycemic Agents\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Drugs and Chemicals\"\n          },\n          {\n            \"abbrev\": \"Gast\",\n            \"name\": \"Gastrointestinal Agents\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT01196546\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"CLMF237ATH01\"\n        },\n        \"organization\": {\n          \"fullName\": \"Novartis\",\n          \"class\": \"INDUSTRY\"\n        },\n        \"briefTitle\": \"Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)\",\n        \"officialTitle\": \"Multi-center, Open-label, 24-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin 50/500 or 50/1000 mg Twice Daily in Patients With T2DM Inadequately Controlled With Metformin\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2017-02\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2010-03\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2011-10\",\n          \"type\": \"ACTUAL\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2011-10\",\n          \"type\": \"ACTUAL\"\n        },\n        \"studyFirstSubmitDate\": \"2010-08-28\",\n        \"studyFirstSubmitQcDate\": \"2010-09-04\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2010-09-08\",\n          \"type\": \"ESTIMATED\"\n        },\n        \"lastUpdateSubmitDate\": \"2017-07-30\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2017-08-01\",\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"type\": \"SPONSOR\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"Novartis\",\n          \"class\": \"INDUSTRY\"\n        }\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Type 2 Diabetes Mellitus\"\n        ],\n        \"keywords\": [\n          \"Type 2 Diabetes Mellitus\",\n          \"vildagliptin\",\n          \"metformin\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"INTERVENTIONAL\",\n        \"phases\": [\n          \"PHASE4\"\n        ],\n        \"designInfo\": {\n          \"allocation\": \"NA\",\n          \"interventionModel\": \"SINGLE_GROUP\",\n          \"primaryPurpose\": \"TREATMENT\",\n          \"maskingInfo\": {\n            \"masking\": \"NONE\"\n          }\n        },\n        \"enrollmentInfo\": {\n          \"count\": 161,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"armsInterventionsModule\": {\n        \"armGroups\": [\n          {\n            \"label\": \"Vildagliptin/metformin\",\n            \"type\": \"EXPERIMENTAL\",\n            \"interventionNames\": [\n              \"Drug: vildagliptin/metformin\"\n            ]\n          }\n        ],\n        \"interventions\": [\n          {\n            \"type\": \"DRUG\",\n            \"name\": \"vildagliptin/metformin\",\n            \"armGroupLabels\": [\n              \"Vildagliptin/metformin\"\n            ]\n          }\n        ]\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"HbA1c reduction\",\n            \"timeFrame\": \"24 weeks after treatment\"\n          }\n        ],\n        \"secondaryOutcomes\": [\n          {\n            \"measure\": \"Proportion of patients who achieve target of HbA1c<6.5% at the end of study\",\n            \"timeFrame\": \"24 weeks after treatment\"\n          },\n          {\n            \"measure\": \"To evaluate the effect of combination therapy of vildagliptin (50 mg) plus metformin (500 or 1000 mg) twice daily on FPG and BMI, safety and tolerability profiles\",\n            \"timeFrame\": \"24 weeks after treatment\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* Type 2 Diabetes mellitus patients who are treated with metformin monotherapy 1,000 mg daily for at least 3 months\\n* The patient is required to have HbA1c 6.5-11.0%\\n* BMI in the range of 22-48 kg/m2\\n\\nExclusion Criteria:\\n\\n* Severe or uncontrolled Type 2 diabetes mellitus (HbA1c\\\\> 11.0%)\\n* Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months\\n* Congestive heart failure requiring pharmacologic treatment\\n* Any of following within past 6 months: (1) myocardial infarction; (2) unstable angina (3) coronary artery bypass surgery or percutaneous coronary intervention\\n* Liver disease such as cirrhosis or chronic active hepatitis\",\n        \"healthyVolunteers\": true,\n        \"sex\": \"ALL\",\n        \"minimumAge\": \"18 Years\",\n        \"maximumAge\": \"78 Years\",\n        \"stdAges\": [\n          \"ADULT\",\n          \"OLDER_ADULT\"\n        ]\n      },\n      \"contactsLocationsModule\": {\n        \"locations\": [\n          {\n            \"facility\": \"BMA Medical College and Vajira Hospital\",\n            \"city\": \"Bangkok\",\n            \"country\": \"Thailand\",\n            \"geoPoint\": {\n              \"lat\": 13.75398,\n              \"lon\": 100.50144\n            }\n          },\n          {\n            \"facility\": \"King Chulalongkorn Memorial Hospital\",\n            \"city\": \"Bangkok\",\n            \"country\": \"Thailand\",\n            \"geoPoint\": {\n              \"lat\": 13.75398,\n              \"lon\": 100.50144\n            }\n          },\n          {\n            \"facility\": \"Phamongkutklao Hospital\",\n            \"city\": \"Bangkok\",\n            \"country\": \"Thailand\",\n            \"geoPoint\": {\n              \"lat\": 13.75398,\n              \"lon\": 100.50144\n            }\n          },\n          {\n            \"facility\": \"Police General Hospital\",\n            \"city\": \"Bangkok\",\n            \"country\": \"Thailand\",\n            \"geoPoint\": {\n              \"lat\": 13.75398,\n              \"lon\": 100.50144\n            }\n          },\n          {\n            \"facility\": \"Siriraj Hospital\",\n            \"city\": \"Bangkok\",\n            \"country\": \"Thailand\",\n            \"geoPoint\": {\n              \"lat\": 13.75398,\n              \"lon\": 100.50144\n            }\n          },\n          {\n            \"facility\": \"Khon Kaen Hospital\",\n            \"city\": \"Khon Kaen\",\n            \"country\": \"Thailand\",\n            \"geoPoint\": {\n              \"lat\": 16.44671,\n              \"lon\": 102.833\n            }\n          },\n          {\n            \"facility\": \"Fort Suranaree Hospital\",\n            \"city\": \"Nakhon Ratchasima\",\n            \"country\": \"Thailand\",\n            \"geoPoint\": {\n              \"lat\": 14.97066,\n              \"lon\": 102.10196\n            }\n          },\n          {\n            \"facility\": \"Maharat Nakhon Ratchasima Hospital\",\n            \"city\": \"Nakhon Ratchasima\",\n            \"country\": \"Thailand\",\n            \"geoPoint\": {\n              \"lat\": 14.97066,\n              \"lon\": 102.10196\n            }\n          }\n        ]\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D003920\",\n            \"term\": \"Diabetes Mellitus\"\n          },\n          {\n            \"id\": \"D003924\",\n            \"term\": \"Diabetes Mellitus, Type 2\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D044882\",\n            \"term\": \"Glucose Metabolism Disorders\"\n          },\n          {\n            \"id\": \"D008659\",\n            \"term\": \"Metabolic Diseases\"\n          },\n          {\n            \"id\": \"D004700\",\n            \"term\": \"Endocrine System Diseases\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"asFound\": \"Diabetes Mellitus\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M7119\",\n            \"name\": \"Diabetes Mellitus, Type 2\",\n            \"asFound\": \"Type 2 Diabetes Mellitus\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M11639\",\n            \"name\": \"Metabolic Diseases\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M25403\",\n            \"name\": \"Glucose Metabolism Disorders\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7862\",\n            \"name\": \"Endocrine System Diseases\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          }\n        ]\n      },\n      \"interventionBrowseModule\": {\n        \"meshes\": [\n          {\n            \"id\": \"D008687\",\n            \"term\": \"Metformin\"\n          },\n          {\n            \"id\": \"D000077597\",\n            \"term\": \"Vildagliptin\"\n          }\n        ],\n        \"ancestors\": [\n          {\n            \"id\": \"D007004\",\n            \"term\": \"Hypoglycemic Agents\"\n          },\n          {\n            \"id\": \"D045505\",\n            \"term\": \"Physiological Effects of Drugs\"\n          },\n          {\n            \"id\": \"D054873\",\n            \"term\": \"Dipeptidyl-Peptidase IV Inhibitors\"\n          },\n          {\n            \"id\": \"D011480\",\n            \"term\": \"Protease Inhibitors\"\n          },\n          {\n            \"id\": \"D004791\",\n            \"term\": \"Enzyme Inhibitors\"\n          },\n          {\n            \"id\": \"D045504\",\n            \"term\": \"Molecular Mechanisms of Pharmacological Action\"\n          }\n        ],\n        \"browseLeaves\": [\n          {\n            \"id\": \"M11667\",\n            \"name\": \"Metformin\",\n            \"asFound\": \"Orally\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M1857\",\n            \"name\": \"Vildagliptin\",\n            \"asFound\": \"Stand\",\n            \"relevance\": \"HIGH\"\n          },\n          {\n            \"id\": \"M10054\",\n            \"name\": \"Hypoglycemic Agents\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M27957\",\n            \"name\": \"Dipeptidyl-Peptidase IV Inhibitors\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M19609\",\n            \"name\": \"HIV Protease Inhibitors\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M14343\",\n            \"name\": \"Protease Inhibitors\",\n            \"relevance\": \"LOW\"\n          },\n          {\n            \"id\": \"M7951\",\n            \"name\": \"Enzyme Inhibitors\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"Hypo\",\n            \"name\": \"Hypoglycemic Agents\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Drugs and Chemicals\"\n          },\n          {\n            \"abbrev\": \"Infe\",\n            \"name\": \"Anti-Infective Agents\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  },\n  {\n    \"protocolSection\": {\n      \"identificationModule\": {\n        \"nctId\": \"NCT05594446\",\n        \"orgStudyIdInfo\": {\n          \"id\": \"2022-A01136-37\"\n        },\n        \"organization\": {\n          \"fullName\": \"Sigvaris France\",\n          \"class\": \"INDUSTRY\"\n        },\n        \"briefTitle\": \"Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot\",\n        \"officialTitle\": \"Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot\"\n      },\n      \"statusModule\": {\n        \"statusVerifiedDate\": \"2023-04\",\n        \"overallStatus\": \"COMPLETED\",\n        \"expandedAccessInfo\": {\n          \"hasExpandedAccess\": false\n        },\n        \"startDateStruct\": {\n          \"date\": \"2022-09-09\",\n          \"type\": \"ACTUAL\"\n        },\n        \"primaryCompletionDateStruct\": {\n          \"date\": \"2023-03-31\",\n          \"type\": \"ACTUAL\"\n        },\n        \"completionDateStruct\": {\n          \"date\": \"2023-03-31\",\n          \"type\": \"ACTUAL\"\n        },\n        \"studyFirstSubmitDate\": \"2022-10-16\",\n        \"studyFirstSubmitQcDate\": \"2022-10-24\",\n        \"studyFirstPostDateStruct\": {\n          \"date\": \"2022-10-26\",\n          \"type\": \"ACTUAL\"\n        },\n        \"lastUpdateSubmitDate\": \"2023-04-09\",\n        \"lastUpdatePostDateStruct\": {\n          \"date\": \"2023-04-11\",\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"sponsorCollaboratorsModule\": {\n        \"responsibleParty\": {\n          \"type\": \"SPONSOR\"\n        },\n        \"leadSponsor\": {\n          \"name\": \"Sigvaris France\",\n          \"class\": \"INDUSTRY\"\n        },\n        \"collaborators\": [\n          {\n            \"name\": \"Clin-Experts\",\n            \"class\": \"INDUSTRY\"\n          }\n        ]\n      },\n      \"oversightModule\": {\n        \"oversightHasDmc\": false,\n        \"isFdaRegulatedDrug\": false,\n        \"isFdaRegulatedDevice\": false\n      },\n      \"descriptionModule\": {\n        \"briefSummary\": \"The aim of the study is to collect morphometric data of legs and feet in diabetic patients in order to model in the laboratory the pressures exerted by compression stockings on different areas of the foot\"\n      },\n      \"conditionsModule\": {\n        \"conditions\": [\n          \"Diabetes\"\n        ],\n        \"keywords\": [\n          \"diabetes\",\n          \"compression stockings\"\n        ]\n      },\n      \"designModule\": {\n        \"studyType\": \"OBSERVATIONAL\",\n        \"patientRegistry\": false,\n        \"designInfo\": {\n          \"observationalModel\": \"COHORT\",\n          \"timePerspective\": \"PROSPECTIVE\"\n        },\n        \"enrollmentInfo\": {\n          \"count\": 89,\n          \"type\": \"ACTUAL\"\n        }\n      },\n      \"outcomesModule\": {\n        \"primaryOutcomes\": [\n          {\n            \"measure\": \"Collection of anthropometric measurements of the foot : Ankle circumference at thinnest point (cm)\",\n            \"description\": \"From the anthropometric data collected, measurements will be made on specific areas by a dynamometric method in the textile laboratory, in particular pressure measurements by different medical compression stockings. These pressure measurements will be estimates of the pressures exerted on areas at risk of the feet of diabetic patients by different medical compression stockings\",\n            \"timeFrame\": \"3 minutes\"\n          },\n          {\n            \"measure\": \"Collection of anthropometric measurements of the foot : Popliteal heel height (cm)\",\n            \"description\": \"From the anthropometric data collected, measurements will be made on specific areas by a dynamometric method in the textile laboratory, in particular pressure measurements by different medical compression stockings. These pressure measurements will be estimates of the pressures exerted on areas at risk of the feet of diabetic patients by different medical compression stockings\",\n            \"timeFrame\": \"3 minutes\"\n          },\n          {\n            \"measure\": \"Collection of anthropometric measurements of the foot : Circumference of the calf at the strongest point (cm)\",\n            \"description\": \"From the anthropometric data collected, measurements will be made on specific areas by a dynamometric method in the textile laboratory, in particular pressure measurements by different medical compression stockings. These pressure measurements will be estimates of the pressures exerted on areas at risk of the feet of diabetic patients by different medical compression stockings\",\n            \"timeFrame\": \"3 minutes\"\n          },\n          {\n            \"measure\": \"Collection of anthropometric measurements of the foot : Circumference of the forefoot at the level of the metatarsal heads (cm)\",\n            \"description\": \"From the anthropometric data collected, measurements will be made on specific areas by a dynamometric method in the textile laboratory, in particular pressure measurements by different medical compression stockings. These pressure measurements will be estimates of the pressures exerted on areas at risk of the feet of diabetic patients by different medical compression stockings\",\n            \"timeFrame\": \"3 minutes\"\n          },\n          {\n            \"measure\": \"Collection of anthropometric measurements of the foot : Radius of curvature estimated by a template, of the head of the first metatarsus (cm)\",\n            \"description\": \"From the anthropometric data collected, measurements will be made on specific areas by a dynamometric method in the textile laboratory, in particular pressure measurements by different medical compression stockings. These pressure measurements will be estimates of the pressures exerted on areas at risk of the feet of diabetic patients by different medical compression stockings\",\n            \"timeFrame\": \"3 minutes\"\n          },\n          {\n            \"measure\": \"Collection of anthropometric measurements of the foot : Radius of curvature estimated by a template, of the head of the last metatarsus (cm)\",\n            \"description\": \"From the anthropometric data collected, measurements will be made on specific areas by a dynamometric method in the textile laboratory, in particular pressure measurements by different medical compression stockings. These pressure measurements will be estimates of the pressures exerted on areas at risk of the feet of diabetic patients by different medical compression stockings\",\n            \"timeFrame\": \"3 minutes\"\n          },\n          {\n            \"measure\": \"Collection of anthropometric measurements of the foot : European shoe size\",\n            \"description\": \"From the anthropometric data collected, measurements will be made on specific areas by a dynamometric method in the textile laboratory, in particular pressure measurements by different medical compression stockings. These pressure measurements will be estimates of the pressures exerted on areas at risk of the feet of diabetic patients by different medical compression stockings\",\n            \"timeFrame\": \"3 minutes\"\n          }\n        ]\n      },\n      \"eligibilityModule\": {\n        \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\n* Patients of both sexes over the age of 18\\n* Patients with diabetes of any type, balanced or not, with or without a history of mal perforating\\n* Giving their oral agreement to participate after information\\n\\nExclusion Criteria:\\n\\n* Patients seen in an emergency\\n* Patient with lower limb amputee (even partial)\\n* Patients with a foot wound, whatever the etiology of the wound\\n* Presence of lymphedema\\n* History of foot trauma with sequelae\",\n        \"healthyVolunteers\": false,\n        \"sex\": \"ALL\",\n        \"minimumAge\": \"18 Years\",\n        \"stdAges\": [\n          \"ADULT\",\n          \"OLDER_ADULT\"\n        ],\n        \"studyPopulation\": \"The recruitment of participants will be done within the framework of the usual consultation of the participating doctor, among the population meeting the inclusion criteria.\",\n        \"samplingMethod\": \"NON_PROBABILITY_SAMPLE\"\n      },\n      \"contactsLocationsModule\": {\n        \"overallOfficials\": [\n          {\n            \"name\": \"Didier RASTEL, PhD\",\n            \"affiliation\": \"SELARL PHILANGIO\",\n            \"role\": \"PRINCIPAL_INVESTIGATOR\"\n          }\n        ],\n        \"locations\": [\n          {\n            \"facility\": \"Rastel Didier\",\n            \"city\": \"Grenoble\",\n            \"zip\": \"38000\",\n            \"country\": \"France\",\n            \"geoPoint\": {\n              \"lat\": 45.16667,\n              \"lon\": 5.71667\n            }\n          }\n        ]\n      },\n      \"ipdSharingStatementModule\": {\n        \"ipdSharing\": \"NO\"\n      }\n    },\n    \"derivedSection\": {\n      \"miscInfoModule\": {\n        \"versionHolder\": \"2025-08-04\"\n      },\n      \"conditionBrowseModule\": {\n        \"browseLeaves\": [\n          {\n            \"id\": \"M7115\",\n            \"name\": \"Diabetes Mellitus\",\n            \"relevance\": \"LOW\"\n          }\n        ],\n        \"browseBranches\": [\n          {\n            \"abbrev\": \"BC18\",\n            \"name\": \"Nutritional and Metabolic Diseases\"\n          },\n          {\n            \"abbrev\": \"BC19\",\n            \"name\": \"Gland and Hormone Related Diseases\"\n          },\n          {\n            \"abbrev\": \"All\",\n            \"name\": \"All Conditions\"\n          }\n        ]\n      }\n    },\n    \"hasResults\": false\n  }\n]"
      }
    ]
  },
  "id": 1
}

[1;33mTesting: FDA Drug Info[0m
[0;32m‚úì PASS[0m (HTTP 200)
{
  "jsonrpc": "2.0",
  "result": {
    "content": [
      {
        "type": "text",
        "text": "[\n  {\n    \"product_ndc\": \"11822-0050\",\n    \"generic_name\": \"Diphenhydramine Citrate, Ibuprofen\",\n    \"labeler_name\": \"Rite Aid Corporation\",\n    \"brand_name\": \"ibuprofen pm\",\n    \"active_ingredients\": [\n      {\n        \"name\": \"DIPHENHYDRAMINE CITRATE\",\n        \"strength\": \"38 mg/1\"\n      },\n      {\n        \"name\": \"IBUPROFEN\",\n        \"strength\": \"200 mg/1\"\n      }\n    ],\n    \"finished\": true,\n    \"packaging\": [\n      {\n        \"package_ndc\": \"11822-0050-1\",\n        \"description\": \"1 BOTTLE in 1 CARTON (11822-0050-1)  / 80 TABLET, FILM COATED in 1 BOTTLE\",\n        \"marketing_start_date\": \"20090624\",\n        \"sample\": false\n      },\n      {\n        \"package_ndc\": \"11822-0050-3\",\n        \"description\": \"1 BOTTLE in 1 CARTON (11822-0050-3)  / 20 TABLET, FILM COATED in 1 BOTTLE\",\n        \"marketing_start_date\": \"20090319\",\n        \"sample\": false\n      },\n      {\n        \"package_ndc\": \"11822-0050-5\",\n        \"description\": \"1 BOTTLE in 1 CARTON (11822-0050-5)  / 120 TABLET, FILM COATED in 1 BOTTLE\",\n        \"marketing_start_date\": \"20230823\",\n        \"sample\": false\n      }\n    ],\n    \"listing_expiration_date\": \"20251231\",\n    \"openfda\": {\n      \"manufacturer_name\": [\n        \"Rite Aid Corporation\"\n      ],\n      \"rxcui\": [\n        \"895664\"\n      ],\n      \"spl_set_id\": [\n        \"d9eefb84-cc2e-4deb-a1c0-a7c21929f5ac\"\n      ],\n      \"is_original_packager\": [\n        true\n      ],\n      \"nui\": [\n        \"N0000000160\",\n        \"M0001335\",\n        \"N0000175722\"\n      ],\n      \"pharm_class_moa\": [\n        \"Cyclooxygenase Inhibitors [MoA]\"\n      ],\n      \"pharm_class_cs\": [\n        \"Anti-Inflammatory Agents, Non-Steroidal [CS]\"\n      ],\n      \"pharm_class_epc\": [\n        \"Nonsteroidal Anti-inflammatory Drug [EPC]\"\n      ],\n      \"unii\": [\n        \"4OD433S209\",\n        \"WK2XYI10QM\"\n      ]\n    },\n    \"marketing_category\": \"ANDA\",\n    \"dosage_form\": \"TABLET, FILM COATED\",\n    \"spl_id\": \"5f945338-3fd2-4b4d-87e2-2405830dd5f6\",\n    \"product_type\": \"HUMAN OTC DRUG\",\n    \"route\": [\n      \"ORAL\"\n    ],\n    \"marketing_start_date\": \"20090319\",\n    \"product_id\": \"11822-0050_5f945338-3fd2-4b4d-87e2-2405830dd5f6\",\n    \"application_number\": \"ANDA079113\",\n    \"brand_name_base\": \"ibuprofen pm\",\n    \"pharm_class\": [\n      \"Anti-Inflammatory Agents\",\n      \"Non-Steroidal [CS]\",\n      \"Cyclooxygenase Inhibitors [MoA]\",\n      \"Histamine H1 Receptor Antagonists [MoA]\",\n      \"Histamine-1 Receptor Antagonist [EPC]\",\n      \"Nonsteroidal Anti-inflammatory Drug [EPC]\"\n    ]\n  }\n]"
      }
    ]
  },
  "id": 1
}

[1;33mTesting: Patient Search[0m
[0;32m‚úì PASS[0m (HTTP 200)
{
  "jsonrpc": "2.0",
  "result": {
    "content": [
      {
        "type": "text",
        "text": "Error executing find_patient: Request failed with status code 401"
      }
    ],
    "isError": true
  },
  "id": 1
}

[1;33mTesting: Error Handling (Invalid Tool)[0m
[0;32m‚úì PASS[0m (HTTP 200)
{
  "jsonrpc": "2.0",
  "result": {
    "content": [
      {
        "type": "text",
        "text": "Error executing invalid_tool: Unknown tool: invalid_tool"
      }
    ],
    "isError": true
  },
  "id": 1
}

[1;33mTest Suite Complete![0m
